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Abstract
Toxic shock syndrome toxin -1 (TSST-1) is a 22kDa extracellular protein 
produced by some strains of Staphylococcus aureus. It is implicated in the 
pathogenesis of toxic shock syndrome, an acute life-threatening multisystem disease.
Eight hybridoma cell lines producing monoclonal antibodies with high binding 
affinity to TSST-1 have been produced and a monoclonal antibody based enzyme- 
linked immunosorbant assay developed. This assay is specific for TSST-1 md no 
cross reaction with a number of other bacterial toxins has been observed. The ELISA 
has been amplified enzymically using biotinylated tyramine and streptavidin 
peroxidase to detect as little as O.lng ml"' of toxin.
Competitive binding studies have indicated the presence of at least three 
antigenic sites on the toxin. The ability of these antibodies to inhibit the mitogenic 
activity of the toxin in T-cell proliferation assays using mouse and human 
lymphocytes has been assessed and results of this work indicate that one of the major 
antigenic sites has an important role in the mitogenicity of the toxin. Binding of the 
antibodies has been localised to the carboxyl terminal region which has been 
implicated in the biological activity of the toxin and several antigenic determinants 
were identified in this region by epitope mapping using polyclonal antibody.
XI
Chapter 1 
Introduction
ChapteJcJlt
Introduction
1.1 The staphylococci.
The staphylococci are members of the family Micrococcaceae. They are Gram 
positive, non motile, facultatively anaerobic, glucose-fermenting cocci, which grow as 
irregular clusters caused by cell division occurring in more than one plane. This gives 
rise to the characteristic "bunch of grapes" ^pearance on microscopic analysis. They 
have a pentaglycine cross bridge in their peptidoglycan, and the cell wall usually 
contains glycerol or ribitol teichoic acids (Schleifer and Kroppenstadt, 1990) which 
have structural functions and are also involved in phage adsorption (Schleifer and 
Steber, 1974) and protein A which can bind immunoglobulin molecules and thus 
agglutinate sera (Moks et al, 1986). Staphylococci are able to tolerate a wide variety 
of environmental conditions, including temperatures from 7 - 48°C (optimum 37°C), a 
pH range frum 4 - 1 0  (optimum 7-7.5) and up to 12% (w/v) salt. Growth of these 
organisms on solid media produces mucoid, smooth, circular, opaque colonies that 
can be white, yellow, grey, or brown in colour. The guanine plus cytosine (G+C) 
content of staphylococci is approximately 30-40% and many staphylococci also carry 
plasmid and phage DNA capable of conferring resistances to antibiotics and heavy 
metals. For instance staphylococci are commonly resistant to penicillin due to a phage 
encoded penicillinase (Arvidson, 1983). A growing problem is resistance to the p- 
lactam drugs, including methicillin. Methicillin resistant Staphylococcus aureus 
(MRSA) have altered proteins in the cell wall which have a very low affinity for 
virtually all P-lactams. MRSA strains are resistant to virtually all other classes of 
antibiotics and account for 30-60% of hospital isolates worldwide (Brickner, 1997).
Most species are natural inhabitants of the mammalian skin and mucous 
membranes and it is estimated that as many as 40% of humans cany these organisms 
(Noble and Somerville, 1974). Coagulase production by these organisms has been 
found to conelate with pathogenicity and all coagulase-positive staphylococci of 
human origin are grouped together as Staphylococcus aureus. The ability to produce 
a polysaccharide capsule is also a feature of clinically important strains. These 
organisms cause a variety of suppurative disease in humans including superficial and 
deep abscesses, wound infections and infection of various internal organs. In addition 
they produce a variety of extracellular virulence factors including hyaluronidase, 
leucocidin, lipase, protease, haemolysins (A-D), exfoliative toxins, staphylococcal 
enterotoxins (SEA-SEH), and toxic shock syndrome toxin-1 (TSST-1; Tranter and 
Brehm, 1994).
1.2 Toxic Shock Syndrome - Epidemiology and Causes.
Several thousand cases of toxic shock syndrome (TSS) have been reported, 
mainly in the USA and to a lesser extent in Europe (Alouf et al, 1991). The majority 
of cases are epidemiologically associated with tampon use in menstruating young 
women vaginally infected with S. aureus (Shands et al, 1980; Davis et al, 1980; 
Blomster-Hautamaa and Schlievert, 1988). However up to 30% of cases may occur in 
other females or males with focal, non-genital S. aureus wound or soft tissue 
infections (Schlievert 1983; Blomster-Hautamaa & Schlievert, 1988). The disease 
results firom release of a toxin (TSST-1) and illness results if the individual has no or 
very low antibody titre to the toxin (Crass & Bergdoll, 1986). Fatality rates for 
menstrual toxic shock syndrome are currently around 6% (Gaventa et al, 1989; 
Alouf et al, 1991). In non-menstrual cases the SE's, especially SEB can also be 
causative agents of toxic shock syndrome (Schlievert, 1986) and it has also been
demonstrated (Arbuthnott et al., 1990; Humphreys et al, 1989) that enterotoxin 
production is more frequent than expected in septicaemia cases compared with strains 
from healthy carriers. Indeed in cases of non-menstrual TSS isolation of bacteria that 
do not produce TSST-1 is common and there is a higher fatahty rate for men and non- 
vaginally infected women compared to vaginal cases (Broome, 1989). Studies of the 
relation between tampon use and TSS suggest that both the degree of absorbency and 
the chemical composition of the tampon are involved although the mechanisms by 
which the risk of TSS is increased are not fully understood (Schlievert, 1993). There 
is also evidence to suggest that the use of contraceptive sponges and diaphrams may 
be linked to an increased risk of non-menstrual TSS (Broome, 1989). TSS resulting 
from the SE's may be significant in S. aureus infected bums (Frame et al, 1985) 
although TSST-1 accounts for many bums-related cases of TSS (Cole and 
Shakespeare, 1990). Adults who do not make a full clinical recovery from TSS have 
been shown to suffer numerous illnesses including a permanent loss of hearing and 
extensive tissue necroses which have been attributed to capillary leakage. 
Streptococcal pyiogenic exotoxins can also be an important cause of toxic shock 
syndrome (Sriskandan and Cohen, 1995; Schlievert, 1993), causing symptoms similar 
to those caused by TSST-1 (Schlievert, 1993). This similarity in disease symptoms 
could be due to the small amount (10-15%) of sequence homology between the 
staphylococcal toxins and the streptococcal toxins (Marrack and K apler, 1990) and 
their common biological properties.
1.3 Clinical symptoms of TSS and susceptibility to disease.
The onset of clinical TSS is abmpt, with symptoms of moderate to severe 
disease including fever, chills, malaise, headache, sore throat, myalgias, muscle 
tenderness, fatigue, vomiting, diarrhoea, abdominal pain and, orthostatic dizziness 
(Chesney er a/., 1984).
Between 24 and 48 hours of the onset of symptoms diffuse erythema, severe 
watery diarrhoea, decreased urine output, cyanosis and oedema of the extremities may 
be observed. Cerebral ischaemia, oedema or a toxin-mediated effect on the central 
nervous system (CNS) rapidly results in somnolence, confusion, irritability and 
agitation (Chesney et al, 1984).
Susceptibility to TSS is very difficult to predict. In menstrual cases there 
^pear to be some pre-disposing factors such as age, tampon usage and vaginal 
colonisation with TSST-1 producing strains of S. aureus. In non-menstrual cases risk 
factors are unknown and colonisation with S. aureus strains producing toxins other 
than TSST-1 is common.
It has been shown that around 90% of the population will have antibody to 
TSST-1 by age 20 (Vergeront et al, 1983) and there is no difference between males 
and females. However it has been shown that 96% of TSS cases reported to the 
Centres for Disease Control in Atlanta have oeeurred in women (Vergeront et al,
1983). The laek of circulating antibody to TSST-1, even in cases of infection with 
TSST-1 producing S. aureus does not predispose TSS however. In one study only 
25% of such cases actually developed symptoms of TSS, and the risk of disease was 
lowest in those who had intravascular infection and higher in individuals with 
cutaneous infections (Jacobson et al, 1989).
In the early 1980's strict criteria were laid down for the clinical diagnosis of 
TSS, and in the absence of a rapid reliable test for TSS these criteria (see Table 1.1) 
remain the only way of making a diagnosis. It is also a priority in cases of TSS to find 
the focus of infection and all S. aureus isolates should be tested for their ability to 
produce TSST-1. Acute and convalescent sera can be assayed for the presence of
antibody to TSST-1 however elevated levels of anti-TSST-1 in acute phase serum are 
unusual (Chesney et al, 1984). Diagnosis must be carefully undertaken so as not to 
confuse clinical conditions such as septic shock (particularly meningococcaemia), 
scarlet fever and urinary tract infections which can present a similar clinical picture to 
TSS.
Frequently however not all the criteria shown in Table 1.1 are fulfilled by a 
particular case. In these instances the illness may be described as probable or possible 
TSS (Marples and Wieneke, 1993). Comparison of symptoms in these cases with 
those seen in confirmed cases may help in diagnosis. In menstrual TSS recurrent 
episodes of the disease may occur and these are often milder than the initial episode 
(Chesney et al, 1984), symptoms such as fever, headache, rash, sore throat, diarrhoea, 
vomiting, dizziness or myalgias should raise the possibility of TSS.
Severe invasive group A streptococcal infections can also produce a toxic 
shock-like syndrome (TSLS; Schlievert, 1993). TSLS is defined by hypotension or 
shock including evidence of two or more multi-organ components (renal impairment, 
coagulopathy, liver involvement, adult respiratory distress syndrome, rash, soft tissue 
necrosis) and the presence of group A streptococci (Breiman et al, 1993). If group A 
streptococci are isolated fi"om an otherwise sterile site TSLS is confirmed whereas if 
the organism is isolated fi-om a nonsterile body site the case is considered probable.
TSST-1 producing staphylococci are also implicated in the pathology of a 
number of other diseases. For example, Kawasaki syndrome (KS) is the main cause of 
acquired heart disease in children (Leung et al, 1993) and is associated with the 
clonal expansion of Vp 2 and Vp 8.1 expressing T-cells (Schlievert, 1993). In most 
cases of KS, TSST-1 producing staphylococci are isolated (ÎÆung et al, 1993)
suggesting that the superantigenic activity of the toxin is a probable cause of the 
illness. TSS and KS share common clinical symptoms; both syndromes induce high 
fever, rash, conjunctivitis, inflammation of the mucous membranes and erythroderma. 
KS is normally a self-limiting disease, but in as many as 25% of cases coronary artery 
abnormalities can develop (Leung et al, 1993).
Recalcitrant erythmatous desquamating disorder (RED) is a variant of TSS 
seen in AIDS patients (Dondorp et al, 1993) and is characterised by prolonged 
erythema, extensive cutaneous desquamation, hypotension, tachycardia and, multiple 
organ involvement (Cone et al, 1991). The isolation of toxigenic staphylococci is a 
common feature of RED cases (Cone et al, 1991). The illness may continue for many 
weeks, often resulting in the patients death (Schlievert, 1993).
Influenza-associated TSS appears to be caused by viral damage to the upper 
respiratory tract followed by subsequent infection with S. aureus. Although the 
infection sites are often non-pyogenic the pH will be near neutrality due to the 
buffering capacity of the blood (Schlievert, 1993) which is ideal for toxin production 
(Schlievert and Blomster, 1983). The fatality rate for influenza associated TSS is 
around 90% in children but lower in adults (Schhevert, 1993).
1.3.1 Therapy.
The most serious problems encountered in the first 24-48 hours of a TSS 
episode include hypotension, myocardopathy, pulmonary oedema, respiratory distress, 
electrolyte disorders and acute renal failure. The r^ id  restoration of intravascular 
volume is most important and can be achieved by the administration of hypotonic 
fluids by the intra-venous route although it is equally important to maintain
respiratory stability. Specific therapy should also be administered to eradicate the 
bacteria. This can be achieved by intravenous administration of antibiotics such as 
oxacillin, piperacillin and clindamycin to kill the micro-organisms and prevent re­
infection.
Studies using the rabbit model of TSST-1 (Bonventre et al, 1988; Best et al,
1988) have indicated that the use of intravenous mouse monoclonal antibody (Mab) to 
TSST-1 can alleviate symptoms of TSS and reduce the mortality compared to 
unimmunised animals. This has lead to the investigation of intravenous 
immunoglobulin (IVIG) as a possible thenqjeutic agent. Fooled human IgG 
preparations have been shown to have high antibody titres to the staphylococcal 
enterotoxins and TSST-1 (Takei et al, 1993) and to be able to neutralise the 
mitogenic effects of these toxins in vitro. The administration of IVIG has also been 
shown to be a highly effective therapy in cases of streptococcal toxic shock, after the 
failure of conventional therapy to improve the patients condition (Barry et al, 1992; 
Perez et al, 1997). Administration of intravenous immunoglobulin during TSS 
neutralises any circulating toxin which can then be cleared fi-om the bloodstream. To 
alleviate symptoms this should be administered along with antibiotic therapy to clear 
the microbial contamination and ensure that no further toxin was produced.
There are currently no therapeutic agents to deal with the effects of the toxin.
1.3.2 Assays for TSST-1.
A number a methods have been developed to detect and quantify TSST-1. 
Solid phase radioimmunoassay (RIA) techniques (Cohen et al, 1983; Hayes et al,
1984) have previously been used to detect TSST-1 in culture supernatant fluids. In
this method the supernatant fluids were placed on a nitrocellulose membrane, dried 
and reacted with rabbit anti-TSST-1 antibody overnight. The bound antibody was then 
detected using ^^ l^odine labelled stq)hylococcal protein A which binds to the Fc 
portion of the antibody molecules. Reeves et al. (1984) used a radial immunodiffusion 
technique utilising rabbit anti-TSST-1 to detect the toxin in clinical isolates, using 
purified toxin as a standard. The sensitivity of this assay was determined to be 5pg 
ml'  ^ which is not adequate to detect toxin in clinical samples where toxin levels can 
be very low (around 7ng m l'\ Wells et al, 1987).
Since then a reverse passive latex agglutination assay (RPLA) assay has been 
developed (Igarashi et al, 1986) which has proved useful when identifying 
toxinogenic cultures of S. aureus, but this method was found to be unsuitable when 
detecting toxin in serum because the serum causes non-specific agglutination (Miwa 
eta l, 1994).
Melish et al (1983, 1989) developed a liquid phase RIA to detect TSST-1 in 
serum, with a detection limit of 0.6ng ml"\ This assay although sensitive and 
reproducible (inter assay variation <7%) suffers the same disadvantages as the sohd 
phase RIA method of Cohen and Hayes in that radioisotopes are used which in 
addition to being hazardous present storage and disposal difficulties. Furthermore 
RIAs require expensive equipment such as scintillation counters to detect the 
radioactivity in the samples.
Various enzyme-linked immunosorbent assay (ELISA) methods for detecting 
toxin have been constructed, most of them use rabbit polyclonal anti-TSST-1 
(Parsonnet et al, 1985a; Rosten et al, 1987). The method developed by Parsonnet 
was a competitive assay method for the detection of toxin in culture supernatant fluids
which necessitated the conjugation of purified TSST-1 to the reporter enzyme alkaline 
phosphatase. This method was sensitive, with a detection limit of 0.5ng ml'  ^ but 
involved overnight incubation of the samples on the assay plate and was therefore 
time consuming. Also the need to incubate overnight might compromise the 
usefulness of this assay when clinical samples are used as they may contain proteases 
or enzyme inhibitors which could affect the assay performance.
Rosten et al. (1987) used a non-competitive assay for the detection of toxin in 
culture supernatant fluids and in vaginal washings fi-om healthy controls as well as 
jfrom women with suspected TSS. Their method had a detection limit of 0.5ng ml'* 
and was successfully used to detect TSST-1 in the clinical samples.
Wells et al. (1987) reported the detection of TSST-1 in urine using an ELISA 
which utilised a rabbit polyclonal C2q)ture antibody and a mouse monoclonsd antibody 
conjugated to horseradish peroxidase (HRP) as the detection reagent. This assay had a 
sensitivity of 0.5ng ml'* and was also used to detect toxin in culture supernatant 
fluids. Kufifiier et al. (1988) developed the ELISA one step further, testing a number 
of Mabs as both capture and detection reagents before optimising conditions for a two 
site Mab based assay. This assay was found to be more sensitive than polyclonal 
antibody based assays, possibly because competition between polyclonal capture and 
detection reagents for common epitopes on the toxin molecule resulted in a lowering 
of the sensitivity of the assay system. The assay was however only qjplied to the 
detection of toxin in culture supernatant fluids and was not used with clinical samples.
Miwa et a l (1994) returned to the use of rabbit polyclonal anti-TSST-1 as the 
capture antibody, but used a biotinylated mouse monoclonal antibody as the detection 
reagent. Avidin-HRP was used as an amplification reagent and a detection limit of
O.Olng ml'* toxin in phosphate buffer was claimed using this system. The assay was 
then applied to the detection of toxin in serum samples taken from TSS patients and 
28 of 60 samples tested were positive, the authors even reported toxin in samples from 
patients who, having had antibiotic therapy were no longer S. aureus culture positive. 
Furthermore these workers suggested that the bacteria may not produce the toxin 
continually and so the timing of samples taken for analysis could be crucial.
Despite the development of all these different assay methods a sensitive, rapid 
and reliable two site Mab based ELISA for the detection of toxin in clinical samples is 
not yet commercially available.
1.4 Structure and characteristics of TSST-1.
TSST-1 is thought to be encoded on a transposon (Kreiswirth et al, 1989) or 
other mobile genetic element which has integrated into the chromosome, like SEB 
which originated on a phage or plasmid (Johns and Khan, 1988) and has also 
integrated into the chromosome, or SED which is encoded by a plasmid which also 
codes for penicillin resistance, (Bayles and landolo, 1989).
TSST-1 is a single chain polypeptide which does not contain any nucleic acid, 
carbohydrate, lipid or cofactor moieties. It has a molecular weight of 22,049 Da as 
deduced from the nucleotide sequence, which translates into 194 amino acids' 
(Blomster-Hautamaa et al. 1986a). TSST-1 does not contain any cysteine residues 
and shares approximately 20% sequence homology with the SE (Betley et al, 1992) 
however X-ray crystallographic studies have shown that there is significant tertiary 
structure homology between SEB and TSST-1, even though TSST-1 lacks the di­
sulphide loop conserved in the SB structure. The absence of a cysteine loop is
10
possibly the reason for the lack of emetic activity in TSST-1 compared to the 
enterotoxins (Tranter et al, 1995).
Purified TSST-1 can exist at 2 different isoelectric points, 7.08 and 7.22, 
possibly due to deamidation during production or purification (Blomster-Hautamaa et 
al, 1986b). The toxin is resistant to hydrolysis with trypsin but can be cleaved using 
papain (Edwin et al, 1988) or pepsin (Reiser et al, 1983). A secondary structure 
analysis of the far-UV circular dichroic spectrum of TSST-1 revealed 6.25% a  helix, 
51.25% p pleated sheets, 9.0% p turns, and 33.5% random turns (Singh et al, 1988a). 
This low a  helix and high P sheet/p turn content has also been found in 
st^hylococcal enterotoxins A, B, C%, and E (Singh et al, 1988b; Singh and Betley,
1989).
The overall structure of TSST-1 as defined by X-ray crystallography is very 
compact, measuring 45x45x58A (Acharya et al, 1994) and reveals that both the 
carboxyl and amino terminal domains contain regions involved in the binding of 
Major Histocompatibility Complex class H (MHC II) molecules and that the C 
terminal domain is implicated in T-cell receptor (TCR) binding (see Fig 1.1).
The area involved in MHC binding encompasses the N-terminal p barrel (Kim 
et al, 1994), in conjunction with residues 170-180 from the C terminal domain 
(Acharya et al, 1994), which fold against the N terminal. Three areas of contact 
between TSST-1 and the human MHC II molecule DRl have been observed (Kim et 
al, 1994) by X-ray crystallographic studies, compared to only two contact areas 
between SEB and DRl (Jardetzky et al, 1994). Despite the proximity of these 
binding sites it is not thought that SEB and TSST-1 compete for binding to DRl 
(Papageorgiou and Acharya, 1997). The site of TCR binding is believed to be made
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up of several structures of the C terminal domain and these areas are on the opposite 
side of the molecule to the MHC binding site (Acharya et al, 1994). The putative 
TCR binding site has also been implicated in the biological activity of the toxin by 
mutagenesis studies. A TSST-1 mutant with an alanine substituted for the histidine at 
position 135 (HI35A) lost its mitogenic effects for T-cells and was unable to induce 
expression of interleukin-2 (IL-2), interferon-y (IFN-y) or tumour necrosis factor p 
(TNF p; Cullen et al, 1995). This inability to stimulate T-cells was not due to a lack 
of binding to MHC II however (Cullen et al, 1995) but rather due to the disruption of 
the TCR binding site as revealed by X-ray crystallographic studies using H I35A 
(Papageorgiou et al, 1996). Other studies (Bonventre et al, 1993; Murray et al, 
1996; Hurley et al, 1996) have also used site-directed mutagenesis to imphcate 
residues in this area in the mitogenicity of the toxin. Table 1.3 hsts amino acid 
residues known to be involved in the biological activity of the toxin and the effects of 
mutation of these residues.
A variant TSST-1 produced by S. aureus isolated frorh an ovine mastitis- 
associated infection has been reported (Ho et al, 1989). This variant toxin has the 
same molecular weight as human TSST-1, however it has an isoelectric point of 8.5. 
Nucleotide sequence analysis revealed that TSST-ovine (TSST-0) had 14 nucleotide 
differences that changed 9 amino acid residues. One nucleotide difference, at position 
514, caused a change to the amino acid charge because glutamic acid at position 132 
was changed to lysine in TSST-0. There is also a change from isoleucine to threonine 
at position 140. Both these changes are in the region implicated in the biological 
activity of TSST-1 and could explain the differences in biological activities between 
the two toxins. Like TSST-1, TSST-0 is mitogenic but it is not pyrogenic and does not
12
enhance endotoxin shock. It is also unable to induce TSS in a rabbit infection model 
(Leee/a/., 1992).
1.5 The Biological Activity of TSST-1.
TSST-1 is one of a number of bacterial and viral products (see Table 1.4) 
which are classified as superantigens (SAgs) because of their ability to stimulate T- 
cells to proliferate non-specifically through interaction with the MHC II on antigen- 
presenting cells (APC) and then the variable region of the p chain of the TCR (see 
Figure 1.2). A superantigen is able to by-pass the normal antigen processing which is 
carried out by APCs such as macrophages, B-cells and dendritic cells (Goodglick and 
Braun, 1994) and bind directly to relatively conserved regions of the MHC II 
molecule (Woodland et al, 1997). Normally antigens are proteolytically cleaved by 
the APC and peptides are displayed in a cleft between the a  and P chains of the MHC 
n  on the cell surface. The T-cell then interacts with the complex on the cell surface 
through the antigen specific TCR which causes release of cytokines such as IL-1 
(Parsonnet et al, 1986; 1985b) INFy and TNF (Parsonnet, 1989) and mediates the 
immune response.
SAgs however, do not require processing by APCs but interact directly with 
areas of the MHC EL outside the normal antigen binding cleft (Hewitt et al, 1992). 
Recent studies however have indicated that peptides already bound in the MHC II 
antigen binding cleft may have influence over the binding of TSST-1, dictating which 
MHC subsets are preferentially bound by the SAg (Woodland et al, 1997, Wen et al, 
1997). This is supported by crystallographic studies which show that part of the 
TSST-1 molecule is positioned over the top of the HLA DRl and possibly interacts
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with MHC bound peptides (Kim et al, 1994). The allele of Class II has less impact in 
SAg presentation than in recognition of conventionally processed peptide + MHC II 
by T-cells (Kapler et al, 1989). The SAg MHC II complex then interacts with the 
TCR such that the SAg binds to the TCR outside the groove area which recognises 
conventionally processed antigens. The toxin does not stimulate all T-cells to respond, 
it is specific for particular Vp sequences and this specificity could explain the 
differential sensitivities of individuals to the toxin (Kappler et al, 1989). TSST-1 is 
specific for the VP2 region and so all Vp2 bearing T-cells are stimulated by TSST-1, 
which results in stimulation of up to 20% of all T-cells leading to massive cytokine 
release and toxic shock (see Table 1.5 for biological properties of TSST-1).
This theory of SAg activity is supported by work utihsing genetically 
engineered mutant TSST-1 toxins. Mutant H I35A which was derived by site-directed 
mutagenesis (Bonventre et al, 1993) was unable to stimulate a mitogenic response in 
T cells, and does not stimulate the cells to express IL-2, ENF-y or TNF p, although it is 
still able to bind to MHC II (Cullen et al, 1995). There was also no production of 
tumour necrosis factor a  which is important in the development of lethal shock. A 
similar mutation at histidine 141 also resulted in a substantial loss of mitogenic 
activity (Blanco et al, 1990), indicating that this area is also critical in the biological 
activity of the toxin. In another study (Murray et al, 1996) the mutant toxins Q136A 
and E132K/Q136K (double mutant) were compared with native toxin and mutant 
H I35A for superantigenicity. It was found that all mutants lost the ability to induce 
lethal TSS, while Q136A was superantigenic but not lethal. These results further 
support the previous observations that this region is involved in the biological activity 
of the toxin.
14
The toxicity of recombinant TSST-1 and mutant toxins in vivo has been 
studied (Bonventre et al, 1993), and the ability of the toxin to stimulate murine T 
cells in vitro and its expression of toxicity leading to lethal shock in rabbits are 
related phenomena.
The high frequency of T-cell activation leads in turn to the overproduction of 
cytokines such as IL-2 and IFN-y from T-cells and EL-1 and TNF from macrophages 
and monocytes. These cytokines are implicated in the pathogenesis of TSS, for 
although they are beneficial in small doses they are known to be toxic at high levels 
(Norgren and Eriksson, 1997), causing fever, weight loss and osmotic imbalances that 
can sometimes lead to death (Parsonnet, 1989). The release of these cytokines is self 
perpetuath)g as the EL-1 induces production of EL-2 which in turn activates cells to 
produce more cytokines.
Although hypotension during the disease process can be explained by capillary 
leakage it is not clear what causes this leakage. Several hypotheses have been put 
forward to explain the involvement of endotoxin in TSS including the release of 
cytokines such as TNF. Fast et a l (1988 and 1989) showed that in the presence of T- 
cells pyrogenic toxins can cause sustained release of TNF although E^ ee et a l (1989 
and 1991) also showed that TSST-1 can alter capillary permeabihty directly. The 
ability of TSST-1 to amplify endotoxin shock (Parsonnet, 1989; Schlievert, 1993) 
may also be important in TSS. Humans have a predominantly Gram negative gut flora 
and there is an increase in Gram negative vaginal colonisation in menstrually- 
associated TSS (Chow et al, 1984a and 1984b) which may indicate that endotoxin is 
important in the cause and severity of hypotension in TSS. Another observation made 
during TSS is the suppression of antibody synthesis; this has been attributed to the
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massive release of IFN-y and may explain why there is a failure to generate antibody 
to the toxin and why so many TSS patients have recurrent episodes of the disease 
(Osterholme, 1982).
1.6 Antibodies, synthesis and structure.
1.6.1 Antibody synthesis.
Antibodies or immunoglobulins (Ig) are synthesized exclusively by B 
lymphocytes. Membrane-bound Ig expressed by B lymphocytes binds antigen in a 
specific reaction, which stimulates the cells to differeritiate into effector cells that 
produce Ig.
Ig hght and heavy chains in common with other secreted and membrane- 
bound proteins are synthesized on membrane bound ribosomes in the rough 
endoplasmic reticulum (RER). The covalent association of the light and heavy chains 
probably occurs in tiie RER as well. The proteins are glycosylated in the RER and the 
Golgi complex before transportation to the plasma membrane in vesicles. The Ig 
molecules then become anchored in the cell membrane or are secreted in a process of 
reverse pinocytosis.
1.6.2 Antibody structure.
All antibodies have a similar overall structure (for general information see 
Abbas et ai, 1991 and Roitt, 1994) which accounts for their common physiological 
features such as charge and solubihty. All antibodies have a common core structure of 
two identical light chains (24 KDa), and two identical heavy chains (50 or 70 KDa). 
Both the light and heavy chains contain a series of repeating homologous units of
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about 110 amino acids which fold independently to form immunoglobulin domains 
(see Fig 1.3).
Antibody molecules can be divided into a small number of distinct classes and 
sub-classes, based on minor differences in physiochemical characteristics such as size, 
charge and, solubihty. In man the classes are A, D, E, G and, M. Members of each 
class have the same isotype. The A and G classes also have sub-classes; Aj and A2 
and Gi to G4. In mice the IgG subclasses are numbered as 1, 2a, 2b and, 3.
Shared regions of the heavy chain amino acid sequence are responsible for the 
common physiochemical and antigenic properties of antibodies of a particular isotype. 
These regions are also responsible for common abilities such as binding to certain cell 
surface receptors or other macromolecules such as complement, which leads to the 
activation of particular immune effector functions. Isotypes and sub-types determine 
the effector functions of humoral immunity. There are two isotypes of antibody hght 
chains. Kappa ( k )  and Lambda (X), but they do not mediate effector functions.
1.6.3. Monoclonal and Polyclonal antibodies.
A solution of monoclonal antibody contains a single antibody specificity and 
affinity and a single immunoglobulin isotype, whereas a polyclonal antibody 
preparation contains a variety of antibody molecules directed against the antigen, as 
well as antibodies which do not react with the antigen of interest.
Polyclonal antibodies are therefore an "average" of the characteristics of ah the 
antibodies in the solution (Zola, 1985). There may be many different antibodies that 
react with the antigen of interest, but minor differences in amino acid sequence can
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result in changes in affinity for the antigen which makes standardisation from one 
batch of reagent to the next extremely difficult.
Mabs however will have a single isotype and a single affinity which can be 
utiUsed in the development of an ELISA. As each different Mab will have one 
specific epitope on the antigen of interest two non-competing Mabs can be used, one 
as a capture antibody, and the other conjugated to a reporter enzyme such as 
horseradish peroxidase as a detection reagent. The Mabs must be carefully screened to 
ensure suitability as ELISA reagents, as epitopes common to a range of antigens, for 
instance the staphylococcal enterotoxins, could allow cross reactivity to occur. Mabs 
also provide excellent opportunity for standardisation as once a clone is established it 
should be possible to produce identical antibody in unlimited amounts.
1.7 Aims of this study.
The aim of this study was to produce and characterise a panel of monoclonal 
antibodies to TSST-1 and to utilise these antibodies in the development of a rapid and 
sensitive ELISA for the detection of TSST-1 in clinical samples such as serum, urine 
and bums fluids.
A number of techniques including epitope mapping (Geysen et al, 1984 and 
Geysen, 1990) and western blot analysis of papain generated fragments of TSST-1 
were used to probe the TSST-1 molecule to identify any antigenically significant 
regions and to provide information on the binding sites of the antibodies.
Finally the antibodies produced in this study were used to provide information 
on the biological activity of the toxin following construction of a T-cell proliferation
18
assay using both mouse spleen cells and human peripheral lymphocytes to study the 
superantigenic activities of TSST-1.
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Table 1.1. Toxic shock syndrome case definition.
1. Fever (temperature >3 8.9®C)
2. Rash (diffuse macular erythroderma)
3. Desquamation, 1-2 weeks after the onset of illness, particularly palms and soles.
4. Hypotension (blood pressure < 90mm Hg)
5. Involveiment of three or more of the following organ systems:
Gastrointestinal (vomiting or diarrhoea at onset of illness).
Muscular (severe myalgia or raised creatine phosphokinase level ).
Mucous membrane (vaginal, oropharyngeal, or conjunctival hyperaemia).
Renal
Hepatic
Haematologic (platelets <10^ ml’*)
Central nervous system (disorientation or alterations in consciousness without 
focal neurologic signs when fever and hypotension are absent).
Chesney e/a/., 1984.
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Table 1.2 Comparison of detection limits of assays for TSST-1.
Method Detection limit (ng ml'*) Reference
Radial immunodiffusion 5000 Reeves era/., 1984
Radioimmunoassay 0.6 Melish er a/., 1983
Competitive ELISA 0.5 Parsonnet er a/., 1985
Non-competitive ELISA 0.5 Rostenera/., 1987
Mab based ELISA 0.06 Kuffiier er a/., 1988
Non-competitive ELISA 0.01 Miwaera/., 1994
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Table 1.4 Suggested bacterial and viral superantigens.
Staphylococcal toxic shock syndrome toxin-1 
Staphylococcal enterotoxins 
St^hylococcal exfoliative toxins 
Streptococcal pyrogenic exotoxins 
Mycoplasma arthritidis mitogen 
Human immunodeficiency virus proteins 
Mouse mammary tumour virus proteins 
Rabies virus nucleocapsid proteins
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Table 1.5. Biological properties of TSST-1
Capacity to induce fever mediated by cytokines from macrophages. 
Enhancement of host susceptibility to lethal endotoxin shock.
Reticuloendothelial system blockade.
Enhancement of delayed type hypersensitivity skin reactions. 
Nonspecific T lymphocyte mitogenicity.
Suppression of immunoglobulin synthesis.
Suppression of chemotaxis of polymorphonuclear leucocytes, induced by 
release of tumour necrosis factor from macrophages.
(Schhevert, 1989)
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Figure 1.1 The polypeptide fold for TSST-1. The MHC II binding region is shaded in 
black while the residues involved in mitogenicity and TCR binding (C-terminal 
domain) are highlighted (Tranter et al, 1995).
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Peptide
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TCR
a
TSST-1
Figure 1.2 T-cell stimulation by superantigen. Model for antigenic stimulation of T- 
cells by superantigens. (A) T-cell recognition of specific antigenic peptide presented 
in conjunction with MHC II by antigen presenting cell, (B) TSST-1 superantigen 
binding to MHC II and TCR V(3 at sites distinct from the conventional peptide 
recognition sites.
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A n t i a p n  K in r l in c r
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212
residues
Heavy 
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residues
Figure 1.3 basic antibody structure. The amino-terminal end of the 
molecule is characterised by sequence variability (V) in both the heavy (H) 
and light (L) chains.The rest of the molecule has a relatively constant (C) 
structure, divided into 3 domains. All domains are stabilised by internal di­
sulphide bonds . The light and heavy chains are held together by di­
sulphide bonds (S) and the hinge region (SS) allows the two antigen 
binding sites to operate independently. Ca denotes carbohydrate moieties.
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Chapter 2
Primary Characterisation of Monoclonal Antibodies
Chapter 2. 
Primary characterisation of monoclonal antibodies.
2.1 Introduction.
Production of monoclonal antibodies can be achieved because each B 
lymphocyte produces antibody of a single specificity. Myelomas are B cell tumours, 
which can occur spontaneously in man and be experimentally induced in animals; 
they also produce single specific antibodies. Myeloma-derived antibodies have proved 
useful for elucidating the structure of immunoglobulin proteins and immunoglobulin 
genes were initially isolated from these cells. The specificity of myelomas however is 
not usually known as the transformation process that affects the B lymphocytes occurs 
randomly. Since normal B lymphocytes of known specificity cannot survive 
indefinitely, Kohler and Milstein (1975) developed a procedure to immortalise the B 
cell by fusing a normal antibody-secreting B cell to a non-secreting myeloma (somatic 
hybridisation). Kohler and Milstein's technique is dependent on the availability of 
cultured myeloma cells that grow in normal growth medium but not in defined 
selection medium because they lack certain functional genes required for DNA 
synthesis. Fusing the myeloma cell to a B cell will provide the necessary genes and 
allow the hybridomas to survive, moreover the B cell is rendered immortal. Myelomas 
can be treated with anti-folate drugs such as aminopterin which block the formation of 
purines and thymidylate, thus blocking DNA synthesis by the de novo pathway. 
Normally these cells would use a salvage pathway to synthesize purine from 
exogenously supplied hypoxanthine using the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRT). Thymidylate can be synthesized from
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thymidine using the enzyme thymidine kinase (TK) so that the hybridoma cells grow 
normally in media supplemented with thymidine and hypoxanthine (HAT medium).
Myeloma cell lines can be made defective in HGPRT and TK synthesis by 
mutagenesis which means that they die in HAT medium. Normal cells fused to 
HGPRT or TK negative cells provide the necessary enzymes to enable the resulting 
hybridomas to synthesize DNA and grow normally in HAT medium. Mouse myeloma 
cells can be fused to normal B cells from immunised mice using a viral system 
(Kohler and Milstein, 1975) or polyethylene glycol (Galfré et a l, 1977) and any 
resulting hybrids can be selected using HAT medium. Any cells that do not fuse die 
while culture wells with growing, fused cells can be tested for antibody to the antigen 
used and positive wells cloned by limiting dilution. The fused cells are known as 
hybridomas and such cells secreting antibody of the correct specificity can be 
selected. The antibodies produced by such hybridomas are called monoclonal 
antibodies (Mab).
Antibodies of the correct specificity identified during the cloning procedure 
must then be characterised prior to purification to ensure that they are of the desired 
immunoglobulin sub-class (Dunbar and Skinner, 1990). Most fusions result in the 
production of either IgG or IgM antibodies. Determination of the Ig sub-class is 
important since it may influence the antibody purification strategy. For example, 
Protein A chromatography which is commonly used in antibody purification binds the 
mouse IgG) sub class with low affinity and for such antibodies affinity 
chromatography on Protein G which strongly binds all mouse IgG sub classes is 
preferred. Any cloned hybridomas producing antibody of the desired specificity can
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be expanded and grown in large volumes in cell culture or as ascitic tumours in 
syngeneic mice to produce large amounts of antibody (Manil et al, 1986).
Further work to characterise the binding of the antibodies to their specific 
antigen which may involve a degree of epitope mapping should also be carried out as 
these studies provide valuable information for the development of immunoassays. It is 
important to select antibodies which bind strongly and are highly specific as false 
positives must be avoided if the assay is to be of any use as a diagnostic tool. On the 
other hand the Mab must provide the desired assay sensitivity and bind to any 
antigenically different forms of the antigen to avoid false-negative assay results. IgG 
antibodies are considered to be the most useful in ELISA development due to the high 
affinity or strength of binding that these molecules have for their specific antigens. 
IgM antibodies bind with great avidity due to their pentameric structure but with a 
lower affinity. They are also particularly sensitive to mild reduction by thiol agents at 
neutral pH, which destroys their high avidity, and makes them less suitable for use in 
ELISA (Tijssen, 1985).
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2.2 Materials and Methods.
2.2.1 Production of monoclonal antibodies to TSST-1.
Anti-TSST-1 monoclonals were produced by immunising BALB/c (Harlan 
Olac) mice with purified TSST-1 (Passalacqua et al, 1992) using a modification of 
the method of Stahli et a l (1983). Four mice were immunised intraperitoneally (i.p.) 
with 25pg of TSST-1 in 0.5ml of a 1:1 mixture of Freunds complete adjuvant (Sigma) 
and phosphate buffered saline (PBS). At intervals of three and six weeks the mice 
were re-immunised by the same method, but using Freunds incomplete adjuvant 
(Sigma). Prior to the fusions single mice were immunised with 50pg of TSST-1 in 
200pl PBS intravenously (i.v.) four days before being culled for spleen removal.
Spleen cells were fused with established P3X63/Ag8.653 myeloma cells 
(ECACC, CAMR, Porton Down, Salisbury) , also derived from BALB/c mice as 
described by Newell et a l (1988). The spleen cells and myeloma cells were mixed in 
a ratio of 3:1 and the cell pellet treated with 50% (v/v) polyethylene glycol solution to 
fuse the cells. The resulting mixture was subsequently resuspended in RPMI selective 
medium (Gibco-BRL) for fused cells containing 20% (v/v) foetal calf serum (FCS; 
Sigma) and 1% (v/v) hypoxanthine-aminopterin-thymidine solution (ICN). The cells 
were dispensed at a concentration of 1.5x10^ myeloma cells per well (lOOpl/well) in 
96 well tissue culture plates (Nunc) containing 6x10^ mouse peritoneal exudate cells 
as feeder cells. The hybridomas were then diluted to an average density of about one 
colony per well and the culture supernatant fluids were assayed by ELISA for 
production of antibody to TSST-1.
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2.2.2 Assay of monoclonal antibodies to TSST-1.
Culture supernatant fluids were added directly to 96 well plates (Immulon 1 , 
Dynatech) which had been coated (lOOpl/well) with lOpg ml’  ^ TSST-1 in PBS, and 
blocked (lOOpl/well) with PBS containing 0.1% (v/v) Tween 20 (Sigma) and 5% 
(v/v) FCS (PBS-T/FCS). After shaking (Denly Wellwarm, 300rpm) at room 
temperature for 90 min the plates were washed 3 times in PBS + 0.1% (v/v) Tween 20 
(PBS-T) and any antibody binding to the toxin was detected using rabbit anti-mouse 
antibody conjugated to horseradish peroxidase (Sigma) previously diluted 1/1000 in 
PBS-T/FCS. After incubation at room temperature for 90 minutes the plates were 
washed 3 times before the substrate solution was added (lOOpl/well). The substrate 
was prepared immediately prior to addition by dissolving 10 mg ml'^ 3,3',5,5'- 
tetramethylbenzidine (TMB; Sigma) in dimethyl sulfoxide (DMSO; Sigma) and 
diluting lOOpl in 10ml of 0.5M sodium citrate buffer, pH 5.0 containing 8 pl 6 % (v/v) 
H2 O2 . The enzymic reaction was stopped after the colour reaction had developed for 5 
min by adding 50pl 2M H2 SO4  to each well and the absorbance read at 450nm on a 
Dynatech MR7000 plate reader.
Culture wells showing significant antibody titres were cloned (Davis, 1986) 
and the supernatant fluids of these cultures tested as before. In total 8  hybridoma cell 
lines producing antibody to TSST-1 were selected for ftirther study.
The isotype of the antibody present in the tissue culture supernatant fluids was 
determined by using a mouse monoclonal antibody isotyping kit (Sigma) according to 
the manufacturer’s instructions.
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2.2.3 Bulk antibody production.
Hybridoma cell lines were expanded in culture by splitting the original culture 
(30ml) between 2 flasks (75cm^ Dow Coming) and adding fresh medium to each to 
return it to the original volume. This process was repeated until confluent growth had 
been produced in 4 flasks. Each cell line was used to inoculate 4 BALB/c mice 
previously primed by i.p. injection with 0 .2 ml pristane (2,6,10,14- 
tetramethylpentadecane. Sigma) per mouse (Hoogenraad and Wraight 1986) , using a 
concentration of 2-5x10^ cells per mouse in 0.5ml RPMI 1640 medium. On 
development of a tumour (generally in 2-4 weeks) a small sample of ascitic fluid 
(approx 200pl) was removed and tested for the presence of antibodies to TSST-1 by 
ELISA. On detection of antibody the tumour was drained whilst the mouse was 
maintained under terminal anaesthesia after which the mouse was culled before 
regaining consciousness. Ascitic fluids were cleared by centrifugation (MSE 
Microcentaur, 13000 rpm for 5 min) and stored at -20°C pending purification. One 
cell line (4 TSST 37.3) when injected into mice produced dry tumours and no ascitic 
fluid could be obtained. This hybridoma cell line was once again expanded in culture 
and used to seed a growth cassette in a Techno Mouse in vitro monoclonal antibody 
culture system (Integra Biosciences). The Techno Mouse culture system makes use of 
hollow fibres to supply a constant flow of culture media to the hybridoma cells 
growing in the cassette, and allows aseptic sampling of the culture for cell 
enumeration and assay of antibody production. In this study 5x10^ hybridoma cells in 
5ml RPMI 1640 media containing 10% (v/v) FCS, 4mM L-glutamine (Sigma), 
penicillin/streptomycin solution (200 lU m f’ and 0.2mg ml"’ respectively; ICN), 
ImM sodium pyruvate (ICN), and 1% hypoxanthine thymidine solution (ICN) were
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injected into the culture chamber. The hybridoma cells were maintained at a constant 
temperature of 37°C in an atmosphere of 5% CO2  for 6  weeks.
2.2.4 Affinity testing of the monoclonal antibodies.
In order to test the binding affinity of the monoclonal antibodies for TSST-1, 
ELISA experiments were conducted in the presence of 3M urea which is a strong 
dissociating agent. ELISA plates (96 well) were coated with toxin at a concentration 
of lOpg ml’' in PBS (lOOpl/well) and blocked using PBS-T/FCS or PBS-T/FCS 
containing 3M urea (lOOpl/well). The antibody was diluted in the same buffer (1/5 
dilutions) in the presence or absence of urea and applied to the plate (lOOpl/well) so 
that the effect of blocking with urea on antibody diluted in normal buffer could be 
compared with the effect of blocking with FCS on the binding of antibody diluted in 
both normal buffer and 3M urea. Bound antibody was detected using anti-mouse HRP 
conjugate (Sigma) diluted 1/1000 in PBS-T/FCS. The enzyme substrate colour 
reaction process was carried out as detailed in section 3.2.2.
2.2.5 Purification of immunoglobulins.
Immunoglobulins from the ascitic fluids and Techno Mouse culture were 
purified by affinity chromatography using protein G Sepharose Fast Flow in user 
prepared HRlO/10 columns (Pharmacia) on a Fast Protein Liquid Chromatography 
(FPLC) system (Pharmacia). All reagents used were high purity, and buffers were 
filtered (0.22pm, Schleicher & Schuell, Anderman) and degassed prior to use. The 
ascitic fluids (4ml) were diluted 1/5 in 20mM sodium phosphate, pH 7.0 and filtered 
using a 0.22pm syringe tip filter (Schleicher & Schuell, Anderman). The sample was
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then loaded onto an 8 ml protein G column and any unbound material washed off by 
running the same buffer through the column until the chart recorder trace had returned 
to near zero. The IgG fraction was then eluted using 3 column volumes of lOOmM 
citric acid, pH 2.7. Immediately following purification the antibodies were dialysed 
into lOOmM Tris pH 8.0 for storage at -20°C. The purity of the antibody preparations 
was assessed by SDS polyacrylamide gel electrophoresis (SDS/PAGE) when the 
purified, dialysed IgG was applied to Pharmacia Phast gels (8-25%) according to the 
manufacturer’s instructions. The antibody was prepared for electrophoresis by heating 
two aliquots (lOpl) of each antibody at 95°C for 5 min in sample buffer, i.e. lOmM 
Tris, pH 8.0 (Sigma) containing ImM EDTA (Sigma) , 2% (w/v) SDS (Sigma), and
0.05% (w/v) bromophenol blue (Pharmacia) as a marker dye. Prior to the heating 
process 50mM dithiothreitol (DTT) was added to one sample.
2.2.6 Specificity of binding of the monoclonal antibodies.
The binding specificity of the monoclonal antibodies was determined by 
coating ELISA plates with each monoclonal antibody separately at a concentration of 
lOpg mb' (lOOpl/ well), and blocking with PBS-T/FCS (lOOp.1/ well). Purified TSST-
1, SEA, SEB, SEC2  and botulinum toxins A, B and E (supplied by R. Brehm and B. 
Hallis, CAMR, Porton Down Salisbury SP4 OJG) which had been diluted in the range 
of lOOng to 0.005ng ml ' in PBS-T/ FCS, were applied to the plates (lOOpl/ well) 
and shaken at room temperature for 90 min. After washing 3 times in PBS-T any 
bound toxin was detected using rabbit polyclonal anti-TSST-1 HRP conjugate diluted 
1/200 in 5% (v/v) FCS in PBS-T. The conjugate had been made previously by 
inoculating a New Zealand White rabbit with purified TSST-1 according to the
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method of de Azavedo et al. (1985), harvesting the resulting serum and purifying the 
immunoglobulin by the method detailed above (section 2.2.5). The immunoglobulin 
was conjugated to horseradish peroxidase by the procedure in section 3.2.1.
2.2.7 Monoclonal antibody competitive binding ELISA
All monoclonal antibodies were tested to determine whether they bound to 
different antigenic binding sights. For this, a 96 well ELISA plate (Immulon 1, 
Dynatech) was coated (lOOpl/well) with purified TSST-1 (5pg ml ') in PBS and 
blocked ( 1 OOpl/well) with PBS-T/FCS, by shaking the plate for 90 min at room 
temperature. Two monoclonal antibodies were initially diluted to 20pg m f' in PBS- 
T/FCS and a further nine 1/3 dilutions made. One of these antibodies in conjugated 
form (see Chapter 3) was initially diluted 1/200 in identical buffer. The samples were 
then applied to the plate (lOOpFwell) such that the conjugate was applied alone and 
also mixed in a ratio of 1 : 1  with each of the other non-conjugated antibodies at all 
dilutions. After incubation at room temperature for 90 min the plates were washed 3 
times before the substrate solution was added ( 1 0 0  pl/well; prepared as described 
above). The enzymic reaction was stopped after the colour reaction had developed by 
adding 50pl 2N H2 SO4  to each well, and the absorbances read at 450nm on a 
Dynatech MR7000 plate reader.
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2.3 Results
2.3.1 Production and characterisation of anti-TSST-1 monoclonal antibodies.
Eight monoclonal antibodies (Table 2.1) were produced as a result of four 
bybridoma fusions. These bybridoma cell lines were expanded in culture and injected 
into mice to produce ascites or in the case of one cell line (4 TSST 37.3) cultured in 
the Integra Biosciences Techno Mouse in vitro culture system.
2.3.1.1 Isotype determination.
Isotype determination carried out on tissue culture supernatant fluids showed 
that all of the bybridoma cell lines produced antibody of the IgG, isotype. The 
antibody titres of the tissue culture supernatant fluids were assayed and found to be in 
the range of 1/3125 to 1/15625. However when assayed in the presence of 3 M urea, a 
strong dissociating agent, most of the Mabs showed a reduction in affinity with some 
titres falling as low as 1/625 (Table 2.1). Although urea can disrupt the conformation 
of the antibody molecule itself, it also disrupts the hydrophobic interactions which are 
important in antibody-antigen interactions. Antibodies which have a much lower 
affinity in the presence of urea may be less suitable for use in immuno-assays as 
components of the sample matrix may affect binding and thus accuracy of the results.
2.3.2 Purification of the monoclonal antibodies.
The Mabs were purified using protein G Sepharose affinity chromatography 
because of the high affinity of protein G for murine IgG,. A typical elution profile 
obtained during antibody purification is shown in Fig 2.1. Purification of the 
antibodies using this method consistantly produced two peaks. The first of these
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contained proteins other than IgG whilst the second peak produced in response to 
lOOmM citric acid, pH 2.7 contained the IgG fraction. The yields obtained by 
purification of antibody from mouse ascitic fluid are shown in Table 2.2. Although 
two antibodies (4 TSST 5.3 and 4 TSST 116.3) produced higher levels of antibody 
(3.4 and 2.7 mg ml"' respectively) all of the other hybridoma cell lines gave under 2 
mg ml"' (range 1.5 - 1.9 mg ml"'). Purification of culture supernatant fluid from the 
Techno Mouse culture of hybridoma cell line 4 TSST 37.3 produced material with a 
concentration of 1 . 8  mg ml"'.
2.3.3 SDS polyacrylamide gel analysis of purified antibody.
Purification of the Mabs using protein G yielded homologous antibody 
preparations (as revealed by SDS PAGE gels) suitable for use in assay development 
and structure/function studies.
The antibody samples treated with DTT (which is used to break the di­
sulphide bonds that hold the various heavy and light chains of the antibody molecule 
together) produced 2 bands on SDS PAGE gels, one corresponding to the light chains, 
with an apparent molecular weight of 25 KDa and one corresponding to the heavy 
chains with an apparent molecular weight of 50 KDa. The samples not treated with 
DTT produced only one band with an apparent molecular weight of 150kDa. An 
example of an antibody purity gel is shown in Fig. 2.2.
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2.3.4 Specificity testing.
To test whether any of the Mabs could bind to toxins other than TSST-1, 
ELISA plates were coated (lOOpl/well) with the Mabs at a concentration of lOpg ml ' 
in PBS. Development of the enzyme substrate colour reaction revealed detection of 
only TSST-1, with no reactivity above background level for any of the other toxin 
types. These tests were carried out to ensure the specificity of binding as the 
staphylococcal enterotoxins share around 2 0 % primary sequence homology with 
TSST-1 (Betley er a/., 1992).
2.3.5 Competitive binding studies.
An ELISA assay was used to determine which of the Mabs competed with 
each other for binding to the toxin. For simplicity the results of these tests are 
summarised in Table 2.3.
Competitive binding ELISA assays carried out using the Mabs conjugated to 
horseradish peroxidase revealed that they could be divided into 3 groups (Table 2.4). 
The members of each group competed with each other for binding to the toxin 
although not with members of other groups. An example of a typical competitive 
binding assay result is shown in Fig 2.3. The conjugated antibody (4 TSST 5.3 HRP) 
alone gives a high signal but when non-conjugated antibody of the same type is added 
the signal is lowered as a function of the concentration of the blocking antibody. Of 
the two other Mabs tested in this experiment one, 4 TSST 10.3, competed for binding 
to the toxin while the other, 4 TSST 23.3, did not and the signal from the conjugate 
was as strong as that from the conjugate alone. These results indicate the presence of 
at least three distinct antigenic sites on the toxin molecule, which appear to be
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supported by the results of the epitope mapping experiments conducted with the rabbit 
polyclonal anti TSST-1 anti toxin (see Chapter 4).
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Table 2.1. Isotype, titres and affinity titres of anti TSST-1 monoclonal antibodies.
Cell line Isotype Titre Affinity titre*
2 TSST 109.3 IgG, 1/3125 1/625
2 TSST 112.3 IgG, 1/15625 1/625
4 TSST 5.3 IgG, 1/3125 1/3125
4 TSST 10.3 IgG, 1/3125 T%25
4 TSST 23.3 IgG, 1/15625 1/3125
4 TSST 37.3 IgG, 1/3125 1/3125
4 TSST 110.3 IgG, 1/3125 1/625
4 TSST 116.3 IgG, 1/3125 1/3125
^Determined in the presence of 3M urea.
Values shown are the mean of three replicate assays.
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Table 2.2. Yield of purified monoclonal antibody produced by growth of hybridoma 
cells in ascites fluid.
Hybridoma cell line Antibody conc.
(mg ml ' )
>
Total volume of 
ascitic fluid (ml)
Total antibody 
yield (mg)
2 TSST 109.3 1.9 6 11.4
2 TSST 112.3 1.5 5 7.5
4 TSST 5.3 3.4 7 23.8
4 TSST 10.3 1.9 5 9.5
4 TSST 23.3 1.5 5 7.5
4 TSST 110.3 1 . 8 5 9.0
4 TSST 116.3 2.7 5 13.5
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Table 2.4 Monoclonal antibody competitive binding groups.
Group 1 Group 2 Group 3
2 TSST 109.3 2 TSST 112.3 4 TSST 5.3
4 TSST 23.3 4 TSST 37.3 4 TSST 10.3
4 TSST 110.3 4 TSST 116.3
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Figure 2.2. SDS PAGE gel of protein G affinity purified Mab to TSST-1. 
Purified Mab was applied to an 8-25% gradient gel both with (lane 2) and 
without (lane 1) DTT. The two bands in lane 2 represent the heavy chains with 
an apparent molecular weight of 50kDa and the light chains with an apparent 
molecular weight of 25kDa. The single band in lane 1 is whole antibody with an 
apparent molecular weight of 150kDa. The multiple bands in lane 3 are 
molecular weight standards (Novex) in the range of 200 - 2.5 kDa.
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Figure 2.3. Competition ELISA assay using 4 TSST 5.3 HRP 
conjugate. The conjugate is applied alone, and with other non­
conjugated antibodies to assess the effects of the non-conjugated 
antibody on the binding of the conjugate to the toxin. This figure 
shows inhibition of binding of 4 TSST 5.3 by 4 TSST 10.3 but not 4 
TSST 23.3.
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2.4 Discussion.
Monoclonal antibodies were generated by immunisation of Balb/c mice 
with highly purified TSST-1 and fusion of antibody secreting B-cells with 
myeloma cells. Such monoclonal antibodies can be used in the investigation of 
structure/function relationships of an antigen and are also useful as reagents in a 
variety of diagnostic methods and assays.
Before their use as reagents in assay systems antibodies must be 
thoroughly characterised to ensure that they are specific for the antigen being 
investigated. All of the Mabs used in this study were of the IgG, isotype; these 
molecules tend to have a higher affinity for their specific antigen than IgM 
antibodies (Liddell and Weeks, 1995) are more stable and easier to use. The 
Mabs were purified using protein G affinity chromatography which gave high 
purity immunoglobulins from a simple one-step procedure and has a 
comparable efficiency to other methods such as DBAE Affi-Gel Blue 
chromatography (Bruck et ai, 1986) and HPLC (Burchiel, 1986).
Purification of the antibodies facilitates efficient conjugation to reporter 
enzymes such as horseradish peroxidase (Manil et al, 1986) for use as detection 
reagents in assay systems. Another advantage of using purified antibody is that 
concentrations of capture and detection reagents can be optimised so that a 
highly sensitive, reproducible assay can be produced using the minimum 
quantities of antibody and enzyme which may also help to reduce background 
noise to a minimum. The higher the quality of reagents used in an immunoassay 
the more specific, reproducible and accurate the results of the assay should be.
4 8
Characterisation of the Mabs is also essential as the specificity of any 
assay system must be absolute. If the assay is to be used as a diagnostic tool 
cross reactivity must be eliminated in order to achieve accuracy of results. The 
lack of cross reactivity of the Mabs with the staphylococcal enterotoxins 
suggests that the 20% homology in amino acid sequence (Betley et al., 1992) 
does not account for any of the antigenic sites identified by the Mabs generated 
in this study. This should allow detection of TSST-1 even in the presence of 
staphylococcal enterotoxins and keep false positive reactions to a minimum. 
High affinity reagents with no potential for cross reaction may also help to keep 
“background noise” to a minimum which is essential if the assay is to be used 
to detect very small amounts of antigen.
The affinity of the antibodies used for ELISA development must be high 
as elements of the sample matrix may interfere with antibody-antigen 
interactions to some extent. Furthermore it is essential during the development 
of a Mab-based ELISA for detection of toxin to use a pair of Mabs that do not 
compete for binding to the target antigen as any competition or steric hindrance 
will result in a loss of sensitivity in the assay system. The method of affinity 
testing using urea, as used in this study is by no means an absolute measure of 
affinity, but studies have shown that the binding of low affinity antibodies is 
reduced in the presence of urea (Hallis et al, 1993), and it gives an indication of 
the behaviour of the Mabs in the presence of interfering factors. Urea affects 
hydrophobic interactions and may disrupt the conformation of the antibodies 
thus influencing binding affinities. If however the antibody-antigen interactions 
rely on charge the presence of the urea will not greatly affect the binding. Of the
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antibodies used in this study, 5 showed reduced binding in the presence of urea 
while 3 did not whilst competitive binding studies revealed that the Mabs could 
be divided into 3 groups, which indicated the existence of at least 3 different 
antigenic determinants on the toxin molecule. In order to increase the 
specificity and reproducibility of the assay Mabs were chosen from non­
competing groups so that one antibody would not influence the binding of 
another to the toxin.
The information generated from the affinity studies together with that 
from competitive binding was used to help identify and select a pair of Mabs to 
use as capture and detection reagents in the development of an ELISA for 
TSST-1.
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Chapter 3 
ELISA Developm ent
Chapter 3.
ELISA Development.
3.1 Introduction.
Since the implication of TSST-1 in the pathogenesis of toxic shock syndrome 
(Todd et al, 1978) various methods have been devised to detect this toxin. Most 
methods involve the culturing of bacterial isolates and assay of supernatant fluids for 
the presence of toxin, although assays for toxin in serum and urine have been 
developed (Wells et a l, 1987; Miwa et al, 1994; Melish et al, 1983). Methods such 
as isoelectric focusing, double immunodiffusion, solid phase radioimmunoassay 
(Cohen et al, 1983; Hayes et al, 1984), reverse passive latex agglutination (RPLA; 
Igarashi et al, 1986) and immunoblotting have also been used, but all are subject to a 
number of limitations, such as labour intensive production of samples, the need for 
special growth media to enhance toxin production, lack of sensitivity and / or 
specificity and prolonged processing time. There are also limitations to use for 
example, as RPLA cannot be used for serum samples because of non-specific 
agglutination caused by serum components (Miwa et al, 1994). The aim of the work 
presented in this chapter was to develop a rapid monoclonal antibody-based assay to 
detect toxin in serum, urine and cultures of clinical isolates.
ELISA has advantages over several of the other methods in that it is a 
sensitive method and detection levels may be as low as pg m f \  It can also be a very 
rapid procedure especially when non-competitive Mabs are used as capture and 
detection reagents.
The use of Mabs in an ELISA for TSST-1 can increase both the specificity and 
sensitivity of the assay. It was found previously (Kuffner et al, 1988) that a
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combination of two non- competing Mabs used as capture and detection reagents may 
provide a similar level of detection to polyclonal antibody reagents. Mabs also have a 
distinct advantage in that successively produced batches of antibody should have 
identical characteristics such as affinity and specificity of binding because they are 
produced from immortal hybridoma cell lines kept in storage at -70°C. Frozen stocks 
of hybridomas can be replenished by growing the cells in culture and then freezing 
down a fresh batch in a special preserving medium containing DMSO. Polyclonal 
antibodies, in contrast, can differ greatly in avidity and affinity from batch to batch 
due to the nature of their production (Dunbar and Schwoebel, 1990). This in turn can 
lead to variation in assay sensitivity and specificity, reducing the effectiveness of the 
assay.
It is important that Mabs be carefully characterised during the development of 
an assay system using screening and selection to evaluate the suitability of the 
reagents. Each different Mab may react differently when used in different situations, 
for instance a Mab that recognises its specific antigen when the antigen is bound to a 
polystyrene assay plate may not be able to bind the antigen when it is immobilised by 
another antibody (Kuffner et ai, 1988). Similarly some of the Mabs may be rendered 
incapable of binding the antigen when used as a capture reagent but are in turn very 
useful as detection reagents when coupled to a reporter enzyme such as horse radish 
peroxidase.
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3.2 Methods.
3.2.1 Conjugation of monoclonal antibody.
All of the monoclonal antibodies in this study were conjugated to horseradish 
peroxidase (HRP) using the method of Nakane and Kawaoi (1974). Five milligrams of 
horseradish peroxidase (Sigma type XII) were dissolved in 1ml of 0.3M sodium 
bicarbonate, pH 8.0 (BDH), containing 0.1ml of 1% (v/v) 1-fluoro-2,4-dinitrobenzene 
(Sigma) in absolute ethanol. The solution was mixed gently at room temperature for 
Ih and 1ml of 50mM sodium periodate (Sigma) added. The mixing was continued for 
a further 30 min before the addition of 1ml 0.16M ethylene glycol (ethanediol; BDH). 
After mixing for a further Ih at room temperature the solution was dialysed overnight 
against 2L of O.OIM carbonate/bicarbonate buffer, pH 9.5 at 4°C. During this time 
5mg of purified immunoglobulin in (2-3 ml) was dialysed against 2L of the same 
buffer.
The dialysed antibody was added dropwise to the dialysed dinitrobenzene 
periodate - horseradish peroxidase mixture over a period of 30 min, mixing 
constantly. Then the solution was mixed for a further 2-3h at room temperature. 
Following this 5mg of sodium borohydride was added and the solution incubated on 
ice for 3h with occasional mixing. The antibody-HRP solution was dialysed overnight 
against 2L of 50mM Tris (Sigma) pH 8.0 containing 0.3M NaCl (Sigma). The 
resulting enzyme conjugate was filtered through an 0 .2 2 pm syringe tip filter 
(Sartorious) and purified to separate bound conjugate from unbound material by gel 
filtration chromatography on a Sephadex G-200 colunrn (bed volume 145ml, diameter 
16mm, height 580mm), previously equilibrated with 50mM Tris, pH 8.0 containing 
0.3M NaCl. The column was eluted at a flow rate of 8 ml h'^  and the eluate collected
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in 2ml fractions. The optical density of the fractions was monitored at 280nm for 
protein content and 405nm for peroxidase activity. Fractions within the A4 0 5  peak 
were pooled and divided into 0.5ml and 50pl amounts for storage at -20°C. The 
activity of the conjugate was tested by ELISA to establish a working dilution which 
would give reliable, reproducible results using the minimum quantity of conjugate.
3.2.2 Enzyme Linked Immunosorbent Assay (ELISA) of TSST-1.
In the standard ELISA assay the 96 well plate (Immulon 1, Dynatech) was 
coated (lOOpl/well) with antibody at a concentration of lOpg ml*' in PBS overnight at 
4°C. The antibody solution was removed by aspiration and the plates blocked with 
FCS/PBS-T as detailed previously (section 2.2.2). The plates were then washed once 
with PBS-T and either used immediately or stored (up to three months) at -20°C for 
future use. A standard curve ranging from lOOng mT  ^ to 0.005 ng mf^ of purified 
TSST-1 diluted in blocking buffer was prepared and applied (lOOpl/well) to the plate. 
The plates were then shaken at room temperature for 90 min, before being washed 
three times with PBS-T. The HRP conjugated detection antibody (diluted 1/300 in 
blocking buffer) was applied and the plates shaken at room temperature as before. 
Finally the plates were washed 3 times with PBS-T before the substrate solution was 
added (100 pl/well). The substrate solution was prepared previously by dissolving 10 
mg m f' TMB (Sigma) in DMSO (Sigma) and diluting lOOpl in 10ml of 0.5M sodium 
citrate buffer, pH 5.0 containing 8 pl of 6 % H2 O2  (BDH). The enzymic reaction was 
stopped after the colour reaction had developed by adding 50pl 2M H2 SO4  to each 
well, and the absorbance read at 450nm on a Dynatech MR7000 plate reader.
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3.2.3 Amplification of HRP in ELISA.
Amplification (Fig 3.1) of the ELISA assay was performed by coating the 96 
well plate (lOOpl/well) with antibody at a concentration of 5pg ml"' in PBS overnight 
at 4°C. The antibody solution was removed by aspiration and the plates blocked with 
FCS/PBS-T as detailed above. The plates were then washed once with PBS-T and 
either used immediately or stored (up to three months) at -20°C for future use. A 
standard curve ranging from lOng ml’^  to 0.0005 ng ml"' of purified TSST-1 diluted 
in blocking buffer was prepared and applied (lOOpl/well) to the plate. The plates 
were then shaken at room temperature for 90 min, before being washed three times 
with PBS-T. The bound toxin was detected using mouse monoclonal anti-TSST-1 - 
HRP conjugates diluted 1/200 in blocking buffer. After washing off any unbound 
conjugate lOOpl of biotinylated tyramine reagent was added to the wells and shaken at 
room temperature for 15 min. This reagent was initially prepared by dissolving 40mg 
tyramine (Pierce) in 1ml DMSO (Sigma) and lOOmg of N-Hydroxysuccinimidobiotin 
(Sigma) in 1ml DMSO before mixing them together in equal volumes. The resulting 
solution was then added to 10ml 50mM Tris pH8.0, containing 0.01% H2 O2  (the 
amount used was determined by experiment, but was usually between 0.03 and 3.0pl 
per ml of buffer). The plate was washed 4 times in PBS-T and lOOpl of Img m f' 
streptavidin peroxidase (Pierce) diluted 1/1000 in blocking buffer added to the wells. 
The plate was then shaken for 15 min at room temperature before being washed again 
4 times in PBS-T. Finally the TMB substrate was added as detailed above with the 
exception that the concentration of TMB used was 6 mg m f \
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3.2.4 Reproducibility of the assay.
Experiments were conducted to measure the reproducibility of the assay 
system using two methods: intra assay variations and inter assay variations (Beer, 
1993). The intra assay variation method tests the variability of results from a set of 
samples which are applied at a number of different points on an ELISA plate, 
compared to the values of a standard curve of toxin, while the inter assay variation 
method measures the variability of results when assays are performed on different 
days.
3.2.4.1 Intra assay variations.
A series of six standard concentrations (8.0, 4.0, 2.0, 1.0, 0.5 and 0.25 ng ml *) 
of toxin in PBS-T/FCS were made and stored at -20°C prior to use. The samples were 
thawed at room temperature and applied to an assay plate such that each dilution 
occupied a different position on each row of sample wells. This determined the effects 
on the results of positioning of the sample on the assay plate. A standard curve of 
toxin in the range of lOng to 0.0005ng mf^ was also applied to the plate and the assay 
completed as described in section 3.2.3. From the results the mean, standard deviation 
and co-efficient of variance (%CV) were calculated.
3.2.4.2 Inter assay variations.
For this the assay was repeated 15 times using the same set of toxin dilutions 
at fixed concentrations on different days and the mean, standard deviation and %CV 
calculated. The standard toxin concentrations consisted of: 10, 3.3, 1.1, 0.37, 0.123, 
0.041, 0.0137 and 0.0045 ng m f\
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3.2.5 Detection of antibody to TSST-1 in human serum.
To detect the presence of antibody to TSST-1 in human serum, ELISA plates 
were coated with toxin at 5pg ml’* and blocked as descibed in section 3.2.2. The test 
sera (from volunteers at CAMR) were then diluted 1/50 in FCS/PBS-T and then a 
further nine 1/3 dilutions were made. The dilutions were applied to the assay plates 
(lOOpl/well) and incubated by shaking at room temperature for 90 min; any unbound 
material was removed by washing as detailed in section 3.2.2. Bound antibody was 
then detected using anti-human IgG HRP conjugate (Sigma) diluted l/IOOO in 
FCS/PBS-T. The enzyme substrate and colour reaction process were exactly as 
described in section 3.2.2 (ELISA).
3.2.6 Spiking experiments.
In these experiments the detection of toxin in human serum and urine was 
compared to the detection of toxin in buffer. The assay was carried out as described in 
section 3.2.3 (Amplified ELISA) but a standard curve of toxin was applied to the 
ELISA plate diluted in either 30% human serum in FCS/PBS-T or 30% urine in the 
same buffer. The serum used in these assays was from a volunteer who had previously 
been found to have no antibody titre to TSST-1 using the method described in section 
3.2.5.
3.2.7 Detection of TSST-1 and antibody to TSST-1 in clinical samples.
A number of serum, plasma and, urine samples from suspected TSS cases 
were obtained and tested for the presence of TSST-1 or antibody to TSST-1 using the 
methods described above. These samples were obtained from: Queens Medical
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Centre, Nottingham, Stoke Mandeville NHS Trust, Southampton General Hospital, 
Russels Hall Hospital, Dudley, and from Booth Hall Children’s Hospital, Manchester.
3.2.8 Detection of TSST-1 in clinical isolates.
Ten culture supernatant fluids from clinically isolated S. aureus strains 
cultured in brain-heart infusion broth (Oxoid) were supplied by Dr. W. Al-Wali at the 
Sheffield PHL, Northern General Hospital, Herries Road, Sheffield S5 7BQ. These 
supernatant fluids were assayed for the presence of TSST-1 using the amplified 
ELISA system described in section 3.2.3. The supernatant fluids were diluted 1/5 in 
blocking buffer containing 10% normal rabbit serum and incubated at 37°C for Ih to 
adsorb any staphylococcal protein A from the sample. Then a further four 1/5 
dilutions made using the same buffer. The diluted samples were applied (lOOpl/well) 
to 96 well assay plates in duplicate along with positive controls of purified TSST-1 at 
concentrations of 0 .1 , 1 . 0  and lOng ml *.
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Figure 3.1 Horseradish peroxidase amplification system.
Biotmyl-tyramine (BT) is added to the assay system. Immobilised HRP catalyses the activation of the phenohc 
group of the tyramine, resulting in the binding of the biotin to tlK sohd phase. The bound biotin is then reacted
with the HRP labelled streptavidin.
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3.3 Results.
3.3.1 Conjugation of the monoclonal antibodies to horseradish peroxidase.
Each of the purified monoclonal antibodies were conjugated to horseradish 
peroxidase and purified by chromatography on a Sephadex G-200 column. A typical 
elution profile showing the purification of the conjugates on Sephadex G-200 is 
shown in Figure 3.2. The resulting purified conjugates were tested by ELISA to 
establish a working dilution. In all cases results showed that diluting the conjugate 
1/200 - 1/300 in blocking buffer would yield adequate sensitivity and reproducibility 
of results in the unamplifled ELISA, while in the amplified assay system the 
conjugate could be used at a dilution of 1/450 and still give reproducible results.
3.3.2 Monoclonal antibody based ELISA for detection of TSST-1.
The Mabs produced in this work were used in a series of initial experiments in 
which different pairs of non-competing antibodies were used as both capture and 
detection reagents. In all cases, the Mab-HRP conjugate was used at a dilution of 
1/300. The limit of detection of TSST-1 in the standard ELISA assay was in the 
region of 1-50 ng mf^ depending on which pairs of Mabs were used. To improve the 
detection limits of the assay to the picogram level, the enzyme signal was amplified 
using biotinylated tyramine and streptavidin peroxidase. Using the amplification 
system each pair of Mabs were further tested as both capture and detecting antibody 
(Table 3.1) values shown in the table represent the lowest toxin concentration to give 
a value of twice the mean of the blank values in the same assay. The combination of 4 
TSST 5.3 as capture antibody and 4 TSST 37.3 HRP as the detection reagent proved 
to offer the most sensitive level of detection (60pg m f'). Figure 3.3 compares a non-
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amplified and amplified ELISA showing differences indetection limits when using 4 
TSST 5.3 as the capture antibody and 4 TSST 37.3-HRP conjugate as the detection 
reagent. After these initial observations, the amplified ELISA based on 4 TSST 5.3 
and 4 TSST 37.3-HRP was studied further in an attempt to increase assay sensitivity 
by optimising the antibody and amplification reagent concentrations.
The capture antibody was tested at concentrations of 10, 5, 2.5 and 1.25 pg 
ml ' (Fig 3.4) and the conjugate diluted 1/200, 1/300, 1/400, 1/500 (Fig 3.5). 
Furthermore biotinylated tyramine was tested (Fig 3.6) at dilutions of 0.03, 0.1, 0.2 
and 0.3 pi ml ' of buffer and the streptavidin-HRP reagent at dilutions of 1/1000, 
1/1500, 1/2000 and 1/2500 (Fig 3.7).
As a result of this assay optimisation the best combination of reagents 
appeared to be: capture antibody 5 pg ml '; conjugate 1/450 dilution; BT 0.1 pi ml ', 
and sHRP 1/1000. Using the reagents at these concentrations it was possible to detect 
as little as lOpg m f' in blocking buffer (Figs. 3.6 and 3.7).
3.3.3 Reproducibility of the assay.
3.3.3.1 Intra assay variations.
Test samples consisting of 6  different concentrations of TSST-1 were assayed 
using the amplified ELISA based on 4 TSST 5.3 and 4 TSST 37.3-HRP. The mean, 
standard deviation and %CV were calculated and are shown in Table 3.2. The results 
demonstrate that the assay is accurate and sensitive with good reproducibility as 
shown by the %CV values which are generally under 10%.
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3.3.3.2 Inter assay variations.
The standard curve of toxin at concentrations of 10 - 0.0045ng m f' was assayed on 
15 different occasions using the method in section 3.2.4, and the results were 
analysed to determine the mean, standard deviation and %CV for each sample 
concentration. The results are shown in Table 3.3 and show high accuracy and low 
%CV values indicating good reproducibility.
3.3.4 Detection of antibody to TSST-1 in human serum.
These experiments were performed using Normal Human Serum (Sigma) and 
sera from colleagues at CAMR. An antibody titre of approximately 1/1350 was found 
to be present in the Sigma serum, and in most of the samples from CAMR staff. There 
were however some samples which showed titres as low as 1/50 and one sample from 
a staff member at CAMR had no detectable antibody to TSST-1 (data not shown). 
This latter serum was subsequently used to develop an assay for detection of toxin in 
the serum of hospital patients with acute phase TSS.
3.3.5 Detection of TSST-1 in human serum and urine.
The detection of toxin in normal dilution buffer was compared to detection in 
buffer containing either 30% serum (Miwa et al, 1994) or 30% urine. Using the 
optimised amplified assay system outlined in section 3.3.2 the recovery from serum 
which had no antibody to TSST-1 (Fig 3.8) and urine (Fig 3.9) was comparable to 
recovery of toxin from FCS/PBS-T buffer. It was noticeable that recovery of toxin 
from "normal human serum" was not possible, probably due to the presence of anti- 
TSST-1 antibodies (results not shown).
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The amplified ELISA assay was applied to the testing of several clinical 
samples of serum and plasma for presence of antibody to TSST-1 and in some cases 
for the presence of the toxin itself. Three urine samples were also assayed for the 
presence of TSST-1. Results from these assays are shown in Tables 3.4 and 3.5.
3.3.6 Detection of toxin in culture supernatant fluids.
The detection of toxin in culture supernatant fluids from TSS clinical isolates 
using the amplified ELISA was compared to that obtained when the supernatant fluids 
were tested using the Oxoid RPLA kit (tests carried out according to the kit 
manufacturers instructions). The results shown in Table 3.6 indicate that the amplified 
ELISA was able to positively identify those samples in which low concentrations (< 
Ing m f') of toxin were present. Such samples were negative or would require 
retesting by RPLA.
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Table 3.2 ELISA detection o f TSST-1 : Intra assay variations.
Pool Toxin standard Mean detectable toxin 
(ng ml ') (ng ml ')
Standard deviation %CV
1 8 . 0 0 7.80 0.55 7.0
2 4.00 4.10 039 7.0
3 2 . 0 0 2.15 0.14 6.5
4 1 . 0 0 1 . 1 0 0 . 1 0 8.9
5 0.50 0.56 0.06 10.7
6 0.25 0.25 0 . 0 2 7.2
Values represent mean figures from 15 assays.
Table 3.3 ELISA detection of TSST-1: Inter assay variations.
Pool Toxin standard Mean detectable value Standard deviation %CV
(ng m l') (ng ml ')
1 1 0 . 0 0 <L938 0.54 5.4
2 3.3333 3333 0.16 4.7
3 1 . 1 1 1 1 1.106 0.09 7.8
4 0.3700 0.367 0 . 0 2 5.1
5 0.1230 0 . 1 2 0 0 . 0 1 4.6
6 0.0410 0.041 0 . 0 0 8 . 1
7 0.0137 0.015 0 . 0 0 16.0
8 0.0045 0.004 0 . 0 0 9.0
Values represent mean figures from 15 assays.
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Table 3.4. Test of urine samples from hospital patients with suspected TSS for
presence of TSST-1.
CAMR reference No. Toxin
DP 356 ND
DP 357 ND
DP 358 ND
6 6
Table 3.5. Test of serum and plasma samples from hospital patients with suspected
TSS for presence of antibody to TSST-1 and / or presence o f toxin.
CAMR reference No. Antibody titre Toxin
ABL 1609 1/50 ND
DP 349 1/450 NT
DP 350 1/50 ND
DP 351 0 ND
DP 352 1/4050 NT
DP 353 1/450 NT
DP 354 0 ND
DP 355 1/1350 NT
DP 359 1/1350 NT
DP 360 1/1350 NT
DP 361 1/50 ND
DP 362 1/1350 NT
DP 363 1/1350 NT
DP 364 1/450 NT
DP 365 1/450 NT
DP 366 1/1350 NT
DP 367 1/450 NT
DP 368 1/1350 NT
DP 369 1/1350 NT
DP 370 1/1350 NT
DP 371 1/1350 NT
DP 372 1/1350 NT
DP 373 1/450 NT
DP 374 1/4050 NT
DP 375 0 ND
DP 376 1/1350 NT
DP 377 1/150 NT
DP 378 1/50 ND
DP 379 1/450 NT
ND - below limit of detection of this assay (0.06ng m f') NT - not tested
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Table 3.6. Detection of TSST-1 produced by clinical TSS isolates of S. aureus.
* Sample number RPLA result ELISA result (ng ml ')
1 -H- > 1 0
2 + 8 . 0
3 ++ > 1 0
4 - 0
5 +/- 0.5
6 -H- > 1 0
7 4-4- > 1 0
8 +/- 0.7
9 - 0.5
1 0 -H 4.0
RPLA results are shown as ++; strong positive, +; positive, +/-;weak positive, or -; 
negative as defined in the kit instruction leaflet.
* Samples are culture supernatant fluids produced by growing the S. aureus isolates in 
brain-heart infusion broth.
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§
<
■  Non-amplified 
•  Amplified
0.6 -
0.0 -J ' 'r I l'ifïin w t i |n ii|
10 ' 10-3 10-2 10 ' 10 ' 10 ' 10 '
Toxin concentration (ng ml ' )
Figure 3.3. Detection of TSST-1 using the amplified and non­
amplified ELISA systems. In both cases 4 TSST 5.3 was used as the 
capture antibody and 4 TSST 37.3 as the detection reagent. Values 
represent the mean of three replicates.
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^  0.6 -<uo
■  1.25 ml' 
#  2.5 m f' 
▲ 5|igm r’
T 10|igmr‘
0.2 -
0.0
Toxin concentration (ng ml '^ )
Figure 3.4. Optimisation of 4 TSST 5.3 capture antibody concentration in 
ELISA for TSST-1. Values represent the mean of four replicate assays.
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Conjugate dilution: 
■ 1/200 
e 1/300 
▲ 1/400 
▼ 1/500
I
o
4J
0.2 -
T oxin  concentration (ng ml )
Figure 3.5. Optimisation of 4 TSST 37.3 HRP conjugate dilution in 
ELISA for TSST-1. Values represent the mean of four replicate 
assays.
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1.0
0.8
o
0.6
Biotinylated Tyramine 
dilutions 
■ 0.03 m1 ml’’
0.4
0.2
0.0
Toxin concentration (ng ml
Figure 3.6. Optimisation of biotinylated tyramine dilution in the 
amplified ELISA for TSST-1. Values represent the mean of four 
replicate assays.
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1.0 -
0.8 -
I0  m
1 
1
< 0.4
0.2
sHRP dilutions 
■ 1/1000 
#  1/1500 
A 1/2000 
T 1/2500
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10 ' 10 ' 10 ' 10 ' 10 ' 10 '
Toxin concentration (ng ml' )
Figure 3.7. Optimisation of the streptavidin HRP conjugate 
dilution in the amplified ELISA for TSST-1. Values represent the 
mean of four replicate assays.
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Figure 3.8. Detection of toxin in human serum. Values represent 
the mean of three replicates.
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Figure 3.9. Detection of toxin in urine. Values represent the 
mean of three replicates.
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3.4 Discussion.
From a panel of eight Mabs, two non-competing antibodies were chosen after 
an extensive selection process to develop an amplified ELISA which can reliably 
detect picogram levels of toxin. A two Mab ELISA for TSST-1 has been developed 
previously (Kuffher et ai, 1988) but these workers appeared to apply this assay to the 
detection of toxin in culture supernatant fluids only and did not verify the assay using 
clinical samples. The detection limit of that assay was 60pg ml'% which is almost 
certainly sensitive enough for the detection of toxin in clinical samples. The assay 
described here would have potential diagnostic value if it could be used to detect 
TSST-1 in the body fluids of hospital patients with suspected TSS. In order to 
investigate this possibility 3 urine and 29 serum and plasma samples from hospital 
patients were assayed for the presence of TSST-1. Despite a sensitive assay for the 
toxin no TSST-1 was detected in any of the clinical samples.
Urine is perhaps the most likely body fluid in which to find the toxin due to 
the cumulative effects of the kidneys (J. Parsonnet, personal communication). This is 
supported by previous observations during research into sudden infant death 
syndrome (SIDS) when i.v. injection of TSST-1 and staphylococcal enterotoxins into 
rats resulted in toxin concentration in the kidneys (Malam et ai, 1992). A number of 
SIDS cases have also been shown to carry increased levels of toxigenic S.aureus 
(Telford et al., 1989) and SEC and TSST-1 have also been detected in kidney tissues 
from SIDS cases (Tranter and Brehm, 1994), indicating a possible role for these 
toxins in the pathogenesis of this disease. Although in all cases the clinical symptoms 
suggested possible TSS and bacteriology samples revealed infection with 
staphylococci which were TSST-1 producers, toxin was not detected in any of the
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plasma or urine samples. The reason for this may have been that the toxin was 
unavailable as it was bound to antibody which was present in most of the serum and 
plasma samples assayed. Such results are at variance from those of previous workers 
(Wells et al, 1987) who reported the detection of TSST-1 in the urine of patients with 
suspected TSS. The amount detected (7ng ml*') in their study was easily within the 
capabilities of the assay developed in this study.
That toxin was not detected in the serum samples was surprising, considering 
detection of toxin in human serum has previously been reported (Miwa et ai, 1994) 
using a rabbit polyclonal capture antibody and a biotinylated mouse monoclonal 
antibody detection reagent. It is entirely possible however that a toxic molecule or 
bacterial product other than TSST-1 was responsible for the symptoms shown by the 
patient, for instance staphylococcal enterotoxin B or a streptococcal pyrogenic toxin 
which have both been implicated in TSS-like illnesses (Schlievert, 1986, Perez et al, 
1997). In support of this some of the patients from whom samples originated were 
also later found to be infected with S.pyogenes. Another possible explanation may be 
that toxin is degraded too rapidly for it to be detected in an antibody-based assay if the 
samples are not processed immediately; prolonged storage or transport at ambient 
temperatures could allow toxin degradation to occur. The majority of samples tested 
in this study had been sent unrefrigerated through the normal post and so could have 
been at ambient temperatures for a considerable time. This would have had an adverse 
effect on chances of detecting toxin in these samples and if an assay was to be used in 
a clinical setting strict control of sample transport and storage would have to be 
maintained. Furthermore it is possible that the toxin was present in such low
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quantities in the samples tested in this study that although it was able to cause clinical 
symptoms detection was not possible.
The amplified ELISA for TSST-1 developed during this work can however be 
used to detect TSST-1 in culture supernatant fluids from clinical isolates and results 
are comparable to, or better than those obtained with a commercial RPLA kit which 
has a sensitivity of Ing ml’* of TSST-1. The ELISA is also a more accurate method 
for the quantification of toxin should this be necessary. The amplified ELISA is not 
only highly specific for TSST-1, but has low %CV values which indicates accuracy 
and reproducibility of results. This is an important consideration if the assay were to 
have a clinical application.
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Chapter 4
I n  v i t r o  Assay Development and Structure/Function Studies
Chapter 4.
In vitro assay development and structure/function studies.
4.1 Introduction.
A principle effect of bacterial superantigens (SAg) such as TSST-1 is the acute 
stimulation of T cells leading to the release of a broad range of cytokines, including 
interleukin-2 (IL-2; Kum et al, 1993) tumour necrosis factor (TNF; Fast et al, 1989), 
gamma interferon (IFN-y; Jupin et al, 1988), and IL-1 (Parsonnet et a l, 1985b) from 
the activated cells. These cytokines are possibly responsible for many of the toxic 
effects of the SAg (Schlievert, 1993). The SAg is able to achieve this situation by by­
passing the normal antigen-specific T-cell activation mechanisms and stimulating a 
relatively large proportion (up to 20%) of the total T-cell population.
The SAg is able to bind to the MHC II on an antigen presenting cell (APC), 
outside the normal antigen binding groove without undergoing any of the proteolytic 
degradation which normally occurs during this process. The SAg then cross links the 
MHC II to the TCR on a T-cell via a conserved region outside the normal antigen 
binding cleft on the TCR, and activates the T-cell, initiating the cascade of cytokine 
release,
A variety of methods have been employed to study the structure/function 
relationships of active proteins. For example chemical fragmentation of TSST-1 using 
cyanogen bromide (Kokan-Moore and Bergdoll, 1989) and enzymic hydrolysis using 
papain (Edwin et al, 1988; Edwin and Kass, 1989) were used to generate toxin 
fragments which could be purified and assayed for biological activity. Mutagenesis 
studies have also been carried out using either random chemical mutagenesis (Kum et 
al, 1996) or point mutations (Murray et al, 1995; Hurley et al, 1995) to induce
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changes in the DNA sequence which change the amino acid sequence of the protein. 
The effects of these changes to the biological activity of the toxin molecule can then 
be assessed and compared to the native protein.
Synthetic peptides representing particular regions of the toxin molecule can be 
made and used in biological assays to assess the importance of the regions they 
represent in the activity of the holotoxin (Soos et al, 1993). Another approach has 
been to generate monoclonal antibodies to the toxin, determine their binding sites on 
the toxin molecule and then assess their effect on the biological activity of the toxin 
(Shimonkevitz et al, 1996). Information from X-ray crystallographic studies 
(Acharya et al, 1994; Prasad et al, 1993) can also be invaluable in defining the 
structure/function relationships of a protein molecule.
The usual approach to combating toxic shock syndrome is to administer 
antibiotics to clear the bacterial infection and hypotonic fluids to counter the fluid loss 
characteristic of this illness. An alternative strategy could however include the 
administration of toxin specific antibodies during the acute stage of the illness. For an 
antibody to have any potential as a therapeutic agent in this disease scenario it must be 
able to prevent binding of toxin to either the TCR or the MHC II and therefore prevent 
cross-linking and stimulation of the T-cell. The work presented in this chapter was 
undertaken to establish whether the Mabs previously described were able to neutralise 
the mitogenic activity of the toxin and therefore limit production of cytokines. 
Another objective was to map the epitopes on the toxin molecule that the Mabs bound 
to. The high specificity of the Mabs suggested that this was feasible and a variety of 
techniques were employed during the mapping process.
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Inhibition of the mitogenic response to TSST-1 by antibodies has been reported 
previously (Bonventre et al, 1988). The Mabs which successfully blocked the in vitro 
proliferation of cells and production of cytokines were also effective in attenuating the 
disease process in rabbits experimentally exposed to TSST-1 in bacterial culture 
supernatant fluids or bacterial cultures producing TSST-1 (Best et al, 1988). These 
workers however did not identify to which epitopes the Mabs were directed; such 
information could be very useful if antibody therapy for the disease condition became 
a practical option in the clinical situation.
Epitope mapping experiments involve the synthesis, on polyethylene pins, of 
protein molecules in a series of overlapping amino acid peptides. The peptides 
displayed on these pins are then reacted with antibodies which bind to epitopes that 
they recognise. Such information can be compared with data from X-ray 
crystallographic studies which may allow localisation of binding sites and give some 
indication of the possible effect antibodies may have on the biological activity of the 
protein.
Cleavage of the toxin by means of enzymic hydrolysis with papain can also be 
used to analyse the binding of the Mabs to the toxin. Papain has been shown to cleave 
TSST-1 into three fragments of 10,12, and 16 KDa (Edwin et al, 1988) and these 
fragments have been sequenced. Separation of the fragments by SDS-PAGE and then 
performing Western blots using horseradish peroxidase conjugated antibodies may 
allow localisation of binding to a particular region of the toxin molecule and by 
reference to the crystal structure the significance of the binding site could be deduced.
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4.2 Materials and Methods.
4.2.1 Papain cleavage of TSST-1.
This work was performed primarily according to the method of Edwin et al.
(1988).
Solid phase papain, covalently bound to agarose beads (Sigma) was re-suspended in 
sterile ultra-pure distilled water at a concentration of 1 0  mg ml * , mixed gently for 1 0  
min and then centrifuged (12000 rpm, 3 min) in a microfuge (MSE) to sediment the 
enzyme. The wash step was repeated and the enzyme re-suspended at a concentration 
of 2 mg ml * in activation buffer consisting of freshly prepared 50mM Tris HCl, pH
6 . 8  containing 50mM L-cysteine HCl and 20mM EDTA. The solution was adjusted 
to pH 7.4 with lOM NaOH immediately before use.
TSST-1 (2mg ml’*) was then mixed with the enzyme slurry such that the ratio 
of toxin to enzyme was 2:1. The enzyme / toxin mixture was then incubated on a 
shaking platform at 37°C for 4h. After this time the reaction mixture was centrifuged 
as detailed above to sediment the solid phase enzyme and the supernatant fluid was 
removed for analysis or storage at -20°C
4.2.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Samples of toxin and the toxin fragments generated by papain hydrolysis were 
prepared for electrophoresis by heating at 95°C for 5 min in lOmM Tris buffer, pH 8.0 
(Sigma) containing ImM EDTA (Sigma), 2% (w/v) SDS (Sigma), 10% (v/v) glycerol 
(Prolabo) and 0.05% (w/v) bromophenol blue (Pharmacia) as a marker dye.
Samples were electrophoresed in 15% polyacrylamide gels (BioRad) using a 
BioRad Mini Protean II discontinuous system as described by Laemmeli (1970).
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Approximately lOpg of protein was loaded into each well. The electrophoresis buffer 
consisted of 192mM glycine (Fisons) and 25mM Tris (Sigma), pH8.3, containing 
0.2% (w/v) SDS (Sigma).
Samples were run at lOOV for 90 minutes before the gels were removed and 
stained in 40% methanol (Hayman Ltd.), 10% acetic acid (BDH) containing 0.1% 
(w/v) Coomassie blue R-250 (Pharmacia) for 2h. This was followed by destaining 
overnight in 40% methanol (Hayman Ltd.) containing 10% acetic acid (BDH). The 
relative molecular mass of the toxin fragments was estimated by comparison of their 
mobility with that of the protein standards (6.5-200 KDa, Boehringer Mannheim) and 
the toxin control.
4.2.3 Western blotting.
The method of Towbin et a l (1979) was followed, with some modifications. 
Following SDS-PAGE of the toxin fragments and whole toxin the staining step was 
omitted and the gel was sandwiched between filter papers and nitrocellulose 
membrane (Amersham Hybond), pre-soaked in transfer buffer consisting of 25mM 
Tris (Sigma) and 192mM glycine (Fisons); pH8.3 containing 20% (v/v) methanol 
(Hayman Ltd.). The gel sandwich was placed in the blotting apparatus with the 
nitrocellulose oriented towards the anode. Proteins were then transferred 
electrophoretically at 50V for 2h using the BioRad Mini Protean II transblot system. 
After transfer of the proteins the nitrocellulose membrane was incubated at room 
temperature overnight in blocking buffer (2% BSA w/v (Sigma) in PBS-T) to block 
any protein binding sites. This was followed by continuous shaking at room 
temperature with either rabbit polyclonal anti-TSST-1 conjugated to horseradish
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peroxidase (diluted 1/500 in PBS-T), or mouse monoclonal anti-TSST-1 HRP 
conjugate (diluted 1/1000 in PBS-T) for Ih,
Unreacted antibody was removed by three 10 minute washes in PBS-T, before 
detection of bound enzyme by the addition of the substrate solution consisting of 
12.5mg TMB (Sigma) dissolved in 5ml methanol (Hayman Ltd), 10ml dioctyl sulpho- 
succinate (lOmg ml’*; Sigma), 0.5ml IM HEPES pH 8,0, 34.5ml distilled H2 O and
12.5 pi 30% H2 O2 ). After colour development (5-10 min) the membranes were 
washed in distilled water and photographed.
4.2.4 Epitope mapping.
4.2.4.1 Octapeptide synthesis on pins.
The TSST-1 molecule was synthesised on polyethylene pins as a series of 
octapeptides encompassing the entire amino acid sequence (Blomster-Hautamaa et al, 
1986a) using a commercially available epitope mapping kit (Cambridge Research 
Biochemicals, Northwich, Cheshire) according to the methods developed by Geysen 
(Geysen, 1990; Geysen et a l, 1984). Synthesis involved sequential ester coupling of 
F-moc (fluorenyl methoxy-carbonyl) protected L-amino acids with t-butyl side chain 
protection. The supplied pins incorporate a flexible protected p-alanine residue 
attached to the pin via hexamethylene diamine acrylic acid.
4.2.4.2 Deprotection of pins.
F-moc N-terminal protection was removed by mild base cleavage. For this the 
pins were gently shaken in a solution of 20% (v/v) piperidine (Sigma) in neat 
dimethyl formamide (DMF; Sigma) for 10 min, washed once in DMF (5 min) and
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four times (2 min per wash) in HPLC grade methanol (Hayman Ltd). The pins were 
allowed to air dry for at least 10 min and washed again in DMF for 5 min before 
insertion into the activated amino acid solutions.
4.2.4.3 Coupling of amino acid residues.
Prior to coupling, the protected amino acids were activated by dissolving the 
freeze dried amino acid in neat DMF containing 30 mmoles of catalytic 1- 
hydroxybenzotriazole to give a final amino acid concentration of 30mM. Aliquots 
(lOOpl) of amino acid residues were dispensed into the appropriate wells of 
polypropylene microtitre trays supplied with the kit. The deprotected pins were then 
inserted into the wells and incubated at 4°C overnight for the coupling reaction to 
occur. Post reaction the pins were washed once in neat DMF (2 min), four times in 
HPLC grade methanol (2 min per wash) and once in neat DMF (2 min) before the 
next round of deprotection.
Deprotection and coupling steps were repeated until peptides of the desired 
length had been generated. The terminal amino acid was deprotected before the N- 
terminal acétylation was performed.
4.2.4.4 N-terminal acétylation.
N-terminal acétylation of the completed peptides was carried out by gently 
shaking the pins in a mixture of DMF, acetic anhydride and diisopropylethylamine 
(50:5:1 v/v/v of the neat solutions) for 90 min. The pins were then washed once in 
neat DMF (2 min) and four times in HPLC grade methanol (2 min per wash) and then 
allowed to air dry.
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4.2.4.5 Side chain deprotection.
Side chain deprotection was performed by washing the pins in a mixture of 
trifluoroacetic acid, phenol and ethane diol (95:2.5:2.5 v/w/v of neat solutions) for 4h 
followed by 2 washes (2 min each) in neat dichloromethane (DCM), two washes (5 
min each) in DCM:diisopropylethylamine (95:5 v/v of neat solutions) and one wash in 
neat DCM (5 min). The pins were then allowed to air dry.
The pin bound peptides were washed in HPLC grade methanol for 18h and 
dried under vacuum. A duplicate series of octapeptides with seven residue overlap 
was synthesised on a separate set of pins. Both sets of pins contained sufficient 
overlapping octapeptides to encompass the entire amino acid sequence of TSST-1.
4.2.4.6 Octapeptide screening.
Peptides were screened using a variation of the manufacturers recommended 
ELISA procedure. Non-specific binding was minimised using 175pi of blocking 
buffer (1% ovalbumin, 1% bovine serum albumin, 0.1% Tween 20, 0.01% sodium 
azide in PBS) per well for Ih at room temperature. The pin bound peptides were then 
placed in 96 well reaction trays containing 150pl/well of the appropriate dilution of 
test antibody in blocking buffer (1/500 dilution of ascites) or neat hybridoma tissue 
culture supernatant fluid, sealed in plastic bags and incubated at 4°C overnight. The 
pins were washed four times (10 min per wash) in PBS-T, before transfer to reaction 
trays containing 150pl/well of Fab fragments of goat anti-mouse antibody conjugated 
to horseradish peroxidase (Amersham International) diluted in PBS-T. The pins were 
incubated at ambient temperature for Ih on a rotary shaker and then washed in PBS-T 
as before. The pins were then transferred to reaction trays containing 150pl/well of
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substrate solution consisting of 50mg 2,2’-azinobis(3-ethylbenzthiazoline-6-sulfonic 
acid) (ABTS; Sigma) dissolved in O.IM disodium hydrogen orthophosphate (BDH) 
and O.IM citric acid (Prolabo), adjusted to pH 4.0. The trays were shaken at ambient 
temperature for up to 30 min to allow colour development. Finally the reaction was 
halted by removal of the pins and the absorbance was read at 405nm using a Dynatech 
MR7000 plate reader.
The resultant peptide-antibody complexes were disrupted for 30 min at an 
initial temperature of 65°C using a sonication bath (Pulsatron 125, Kerry Ultrasonics) 
containing approximately 500ml of disruption buffer (1% SDS and O.IM sodium 
dihydrogen orthophosphate adjusted to pH 7.0 (BDH) to which 0.1% (v/v final 
concentration) 2-mercaptoethanol (BDH) was added). The pins were then washed 
twice for 1 min in hot distilled water (60-70°C) and then submerged in gently boiling 
methanol for 2 min. Finally the pins were allowed to air dry before re-use or storage at 
4°C over silica gel.
The reproducibility of the peptide screening assay was assessed each time by 
the inclusion of two control peptides conjugated to pins provided by the kit 
manufacturer. One of these (a positive control) consisted of a pin of a pre-synthesized 
tetramer (PLAQ) which reacts with a mouse monoclonal antibody (provided by the 
manufacturer), the other (negative control) tetramer (GLAQ) does not react with this 
mouse monoclonal antibody. Both of these control tetramer peptides were synthesized 
de novo at the same time as the TSST-1 octamers to monitor the effectiveness of the 
peptide synthesis.
4.2.5 T-cell proliferation assay.
A murine spleen cell assay was developed so that the ability of the monoclonal 
antibodies to inhibit the mitogenic activity of the toxin could be assessed. For each 
assay a BALB/c mouse was killed by cervical dislocation and the spleen was removed 
and placed in a universal containing 10ml of warmed (37°C) medium (RPMI 1640 
containing 10% FCS, 2mM L-glutamine, penicillin / streptomycin solution ( 200IU 
mr*/200pg ml * final concentration ), 5mM HEPES and ImM sodium bicarbonate). 
The spleen cells were harvested by forcing the spleen through a cell strainer (Falcon) 
and then centrifuging (5 min at lOOOrpm) in 15ml of warmed medium. The 
supernatant fluid was poured off and the cells resuspended in 1 ml of red blood cell 
lysing solution (Sigma) and gently mixed for 1 min prior to the addition of 14ml of 
medium. The cells were harvested by centrifugation as before, the supernatant fluid 
was removed and the cells resuspended for counting in 10ml of medium. The cells 
were diluted to 8x10^ cells ml * and 50pl of cell suspension added to each well of a 96 
well tissue culture plate. Dilutions (1/3) of TSST-1 in culture medium were added to 
the wells (in triplicate), covering a range of final concentrations from lOOng to 
0.005ng ml '*. Normal culture medium was used as a negative control, and 
Concanavalin A (Sigma) added to other wells to act as a positive control. The plate 
was incubated at 37°C in 5% CO2  for 72h, after which lOpl of Alamar blue"^  ^
(Serotec) was added to each well and incubation continued as before for 4h. The 
absorbance of the plate was then read at 570nm and 600nm on a Multiskan plate 
reader (Labsystems). The mean value for each of the triplicate samples was calculated 
and those at 600nm subtracted from the mean 570nm values. The resulting values 
were used to prepare a graph of mitogen concentration vs absorbance. This assay was
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also used to assess the ability of the monoclonal antibodies to inhibit cell proliferation 
by adding lOpg ml'* (final concentration) monoclonal antibody to wells when the 
toxin was added and measuring the response of the cells to the toxin both in the 
presence and absence of antibody.
4.2.6. Interleukin 2 assays
The T-cell mitogenicity assay described above was also employed to study the 
effect of TSST-1 on interleukin 2 (lL-2) production by spleen cells by removing the 
culture supernatant fluids and assaying for the presence of lL-2.
For this 96 well ELISA plates were coated (lOOpl/well) overnight with a rat 
anti-mouse lL-2 monoclonal capture antibody (Pharmingen) at a concentration of 2pg 
ml * diluted in lOmM sodium carbonate pH 8.0 and blocked with 10% FCS in PBS 
(200 }il/well) for 2h at room temperature. Culture supernatant fluids from mouse 
spleen cells stimulated by TSST-1 in the presence or absence of monoclonal antibody 
were then transferred directly to the ELISA plates, which were incubated at room 
temperature for 4h. After 4 washes with PBS-T a biotinylated rat anti-mouse lL-2 
detection antibody (2pg ml * ; Pharmingen) was added, diluted in PBS-T containing 
10% FCS (lOOpl/well) and incubated at room temperature for 45 min. The plates were 
then washed 6  times and Img ml * avidin-peroxidase (Sigma) previously diluted 
1/400 in PBS containing 10% FCS was added, and the plates incubated for 30 min at 
room temperature. After 8  washes with PBS-T, the ABTS substrate solution (see 
Section 4.2.4.6 ) in O.IM citric acid, pH 4.35 containing lOpl H 2 O2  per 10ml of 
substrate solution was added (lOOpl/well). The absorbance of the resulting reaction 
was determined at 405nm on a Dynatech MR7000 plate reader.
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4.2.7 Human peripheral blood lymphocyte assay.
A sample of blood (up to 30ml) was taken from a volunteer and diluted 1/2 
with RPMI 1640 medium (Gibco-BRL) containing penicillin/streptomycin (ICN; 
2001U ml * /200pg ml’* final concentration respectively), 10ml 5.5% sodium 
bicarbonate (ICN), 5ml IM HEPES buffer, pH 7.5 (ICN) and 5ml 200mM L- 
glutamine (Sigma) per 500ml. The diluted blood (20ml aliquots) was layered onto 
15ml Lymphoprep (Nycomed Ltd) and centrifuged at 400xg (RT 600B centrifuge; 
Dupont) for 30 min at 4°C.
The layer containing the lymphocytes was removed using a pipette into a fresh 
tube and the volume made up to 40 ml with RPMI 1640 as above, but also containing 
10% FCS (Sigma). The tubes were then centrifuged again as before and the 
supernatant fluid discarded. Finally the pellet containing the lymphocytes was 
resuspended in 15ml medium (as above) for counting. The cells were diluted to 1x10^ 
cells per ml and 50pl of cell suspension added to each well of a 96 well culture plate. 
Dilutions (1/3) of TSST-1 in culture media were added to the wells (in quadruplicate), 
covering a range of final concentrations from lOOng to 0.005ng ml ’*. Normal culture 
medium was used as a negative control and Concanavalin A added to other wells to 
act as a positive control. The plate was incubated at 37°C in 5% CO2  for 96h.
The proliferation induced by the toxin was measured using a Biotrak"^^ cell 
proliferation assay kit (Amersham), according to the manufacturers instructions.
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4.3 Results.
4.3.1 Papain cleavage of TSST-1.
Proteolysis of purified TSST-1 using papain resulted in the production of three 
peptides of approximately 10, 12, and 16 KDa due to cleavage of the tyrosine 52 - 
serine 53 and glycine 87 - valine 8 8  peptide bonds (Edwin et al, 1988). These 
fragments were separated electrophoretically on SDS PAGE gels, as shown in Figure 
4.1.
4.3.2 Western blot analysis of papain generated TSST-1 fragments.
The papain generated TSST-1 fragments were electrophoresed and then 
transferred to nitro-cellulose membranes which were probed subsequently with the 
anti-TSST-1 HRP conjugates in an attempt to localise the binding of the Mabs on the 
toxin molecule. All of the Mabs appeared to bind to the 12 and 16 KDa fragments. 
Figure 4.2 shows an example of a Western blot experiment comparing binding of 
monoclonal antibody 4 TSST 5.3-HRP and rabbit polyclonal anti TSST-HRP to the 
TSST-1 fragments. It can be seen that there is still a band of uncleaved toxin above 
the fragments and the rabbit polyclonal binds to all three toxin fragments, whereas the 
Mab identifies only the 12 and 16 KDa fragments. The 12 KDa fragment makes up 
75% of the 16 KDa fragment, and these fragments are situated at the carboxyl end of 
the holotoxin. These results indicate that the Mabs all bind within the COOH terminal 
domain of the toxin where several antigenic determinants were also identified using 
rabbit polyclonal anti-serum in the epitope mapping experiments (see section 4.3.3). 
This region has also been implicated in the biological activity of the toxin (Edwin et 
al, 1988, Cullen e/û/., 1995).
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4.3.3 Epitope mapping.
Initial epitope mapping experiments were carried out by reacting the epitopes 
displayed on the pins with rabbit polyclonal anti-TSST-1 serum in order to establish 
the antigenic profile of the toxin and to allow a direct comparison with any epitopes 
which may have been highlighted by the Mabs. The antigenic profile of the toxin as 
defined by the rabbit polyclonal anti-serum is shown in Fig 4.3. The polyclonal serum 
identifies three major antigenic sites, in addition to four minor epitopes. A positive 
reaction was deemed to be one where the absorbance value was at least twice the 
value of the background binding which was defined as an average of the lowest 25% 
of absorbance figures. Residues of the primary sequence corresponding to the 
antigenic sites are detailed in Table 4.1. Reaction of the TSST-1 pins with the Mabs 
failed to highlight any of the linear epitopes displayed on the pins, with no reactivity 
above background levels seen in any assay.
As a control the rabbit polyclonal antibody was re-tested after testing all of the 
Mabs to make sure that the pins were still working satisfactorily and that the 
procedure had been carried out correctly. The second assay (results not shown) with 
the rabbit antibody yielded results identical to those of the first test, proving the 
reproducibility of the assay technique and the integrity of the pins. The results again 
highlighted the 7 antigenically important epitopes. One epitope, which includes 
residues 137-148 overlaps a region of the molecule containing residues 132-144 
which are known to affect mitogenic activity (Acharya et al, 1994, Blanco et al, 
1990, Bonventre et al, 1993). Also identified by this antibody is an epitope between 
residues 172 and 191 which includes residues 170-180 predicted to be involved in 
MHC II binding (Acharya et al, 1994).
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4.3.4 T cell proliferation assays.
The T cell proliferation assay was developed to show the mitogenic activity of 
the toxin. Once the protocol had been established Mabs were introduced to assess 
their ability to neutralise the mitogenicity of the toxin in vitro.
A  comparison of the Mabs in an attempt to neutralise the activity of TSST-1 
showed that not all of them were able to limit the mitogenic activity of the toxin (see 
Table 4.2). The ability to neutralise the toxin in vitro corresponded with the grouping 
of the Mabs in the competitive binding experiments (see section 2.3.5), in that one 
group neutralised the toxin while the other two groups did not. Although the Mabs 
were able to neutralise the toxin in vitro these results did not indicate whether the 
Mabs were binding to the epitope of the toxin which binds to the Vp segment of the 
TCR or if they were binding to the MHC II binding region of the toxin. Polyclonal 
rabbit anti TSST-1 was also used in the proliferation assay to provide a direct 
comparison with the Mabs.
The effects of the Mabs on the mitogenicity of the toxin can be seen in Fig 4.4. 
Monoclonal antibody 4 TSST 5.3 has neutralising ability when used at a concentration 
of lOpg ml * , and cell proliferation is prevented while 4 TSST 37.3 does not affect 
the mitogenicity of the toxin when used at the same concentration.
4.3.5 Interleukin 2 assays.
The effects of the Mabs on production of IL-2 by T-cells proliferating in 
response to stimulation with TSST-1 was investigated as a follow up to the study on 
inhibition of mitogenicity. Results showed that all of the Mabs which inhibited 
mitogenicity also inhibited expression of IL-2, while those that did not inhibit cell
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proliferation had little or no effect on cytokine production. This result concurs with 
the findings of other workers (Bonventre et al, 1988) who found that cytokine 
production was inhibited by neutralising antibodies. Figure 4.5 illustrates the 
production of IL-2 in the presence of TSST-I and also when neutralising (4 TSST 5.3) 
and non neutralising (4 TSST 37.3) Mabs were present.
4.3.6 Human Lymphocyte proliferation assays.
This assay was developed to demonstrate the mitogenic effect of the toxin on 
human peripheral blood lymphocytes and assess the ability of the Mabs to neutralise 
the effects of the toxin in vitro.
The results of this work were similar to the results of the mouse T-cell 
proliferation assays (Section 4.3.4) in that the Mabs ability to neutralise the toxin 
corresponded to their competition groups. Mabs 4 TSST 5.3, 10.3, and 116.3 were 
able to neutralise the toxin, while the other Mabs had no effect on the mitogenicity of 
the toxin. Figure 4.6 shows the proliferative effects of the toxin on the lymphocytes 
and the effects of neutralising (4 TSST 5.3) and non-neutralising (4 TSST 37.3) Mabs 
on mitogenicity.
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Figure 4.1. Electrophoresis of papain generated TSST- 1  fragments.
P^m n generated TSST-1 fragments (see section 4.2.1) were applied to a 15% SDS-
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Figure 4.2. Western blot analysis of papain generated TSST-1 fragments.
TSST-1 and papain generated toxin fragments were electrophoresed and transferred 
to nitrocellulose membranes. These were then probed with either rabbit polyclonal 
anti-TSST-1 HRP conjugate (lanes 2 and 3) or mouse monoclonal anti-TSST-1 HRP 
conjugate (lanes 5 and 6 ). The polyclonal antibody reacts with all three fragments as 
well as the holotoxin while the Mab (4 TSST 5.3) reacts with only the 16 and 12 kDa 
fragments and holotoxin. Pre-stained molecular weight markers (Bio-Rad) were used 
(range 202-6.9 kDa; lanes 1 and 4).
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Table 4.1 Identification of antigenic sites during epitope mapping of TSST-1 
octapeptides using rabbit polyclonal anti-toxin.
Antigenic site* Octapeptide numbers Corresponding amino acid 
residues of primary 
sequence
1 4-9 4-16
2 40-52 40-59
3" 57-62 57-69
4 75-98 75-105
5" 133-145 133-152
6 151-168 151-175
t 172-182 172-189
* An antigenic site was one which gave a significant absorbance reading above the 
background level which was defined as an average of the lowest 25% of absorbance 
figures.
 ^indicates major antigenic site as identified in Figure 4.3
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Figure 4.3. Antigenic profile o f  TSST-1 identified by epitope mapping o f  primary sequence octapeptides
using rabbit polyclonal antibody
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Table 4.2 Identification of neutralising monoclonal antibodies by in vitro inhibition 
of TSST-1 induced proliferation of mouse spleen cells in vitro.
Neutralising antibodies Non-neutralising antibodies
4 TSST 5.3 2 TSST 109.3
4 TSST 10.3 2 TSST 112.3
4 TSST 116.3 4 TSST 23.3
4 TSST 37.3
Rabbit polyclonal 4 TSST 110.3
100
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#  Cells + toxin + Mab 5.3 
A Cells + toxin + Mab 37.30.30 -
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Figure 4.4. The mitogenicity of TSST-1 in a mouse spleen cell assay, and 
neutralising effect of Mab 4 TSST 5.3, compared to the effect of Mab 4 TSST 
37.3 (final antibody concentration lOpg ml'*).
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Figure 4.5. Production of IL-2 by TSST-1 stimulated mouse spleen cells, 
in the presence and absence of neutralising (4 TSST 5.3) and non­
neutralising (4 TSST 37.3) monoclonal antibody (final antibody 
concentration lOpg mb').
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Figure 4.6. Neutralisation of TSST-1 in the human lymphocyte 
proliferation assay. Mab 4 TSST 5.3 neutralises the mitogenic effect of 
the toxin while 4 TSST 37.3 does not (final antibody concentration lOpg 
m l'^.
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4.4 Discussion.
Epitope mapping experiments failed to indicate the binding sites within TSST- 
1 of any of the Mabs. The reasons for this may be several fold but may include that 
the Mabs bind to conformational epitopes, or that the octapeptides did not produce 
long enough linear epitopes for recognition by the Mabs. The antigenic profile 
generated by the rabbit polyclonal antibodies was of great interest, as it highlighted 
several epitopes throughout the linear peptide sequence. These results complemented 
the findings of structure-function studies of other workers by highlighting epitopes in 
regions shown to be involved in the biological activity of the toxin. For instance 
residues 50 and 53 in the TSST-1 amino acid sequence have been shown to interact 
with the human major histocompatibility molecule DRl (Kim et a l, 1994) and these 
residues are highlighted in a region encompassing residues 40-59 in the antigenic 
profile. Similar interactions are seen between SBB and DRl, which are also known to 
interact (Kappler et al, 1992).
Early studies using cyanogen bromide generated fragments (Blomster- 
Hautamaa et al, 1986b) revealed that a fragment composed of amino acids 34-158 
bound to antibodies that blocked the mitogenic and immunosuppresive functions of 
TSST-1. There are several epitopes within this peptide that were highlighted by the 
polyclonal antibody epitope mapping (peptide numbers 40-52, 57-62, 75-98, 133-145 
and 151-168) and some of these epitopes are also included in the 12kDa COOH 
terminal region of the toxin molecule spanning residues 88-194 identified by Edwin et 
al (1988 & 1989) to be important in the biological function of the toxin. The 12kDa 
papain generated fragment studied by Edwin et a l (1988) was found to be
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serologically active by means of a competitive ELISA and capable of inducing a 
proliferative response in human peripheral blood lymphocytes.
Much work has also been done using site-directed mutagenesis to identify 
biologically important regions of the toxin. The work of Blanco et al. (1990) and 
Bonventre et a l (1993) has implicated residues between 115 and 144 in the toxin’s 
mitogenic activity. Mutation of the histidine residue at position 135 abolishes 
mitogenic activity although it does not affect recognition of the mutant toxin molecule 
by a Mab that neutralises mitogenicity of the native toxin in vitro and in vivo 
(Bonventre et al. 1993). Substituting the histidine residue at position 141 with alanine 
also affects the mitogenicity of the toxin, although unlike residue 135, histidine 141 is 
buried in the structure of the toxin and mutation here probably results in 
conformational changes to the structure of the toxin (Acharya et al, 1994). Other 
studies have also shown the importance of the region including residue 135. Hurley et 
al (1995) have shown that the TCR binding site consists of a region contained within 
residues 127-150, which is located on the central long a  helix and residues 10-16 
which are in the NH2  terminal short a  helix and loop structure. There is also possible 
involvement in TCR binding of residues in the loop formed by residues 97-116 and 
mutation of the tyrosine at position 115 has been shown to diminish binding of a 
neutralising antibody (Blanco et al, 1990). All of these areas are highlighted as 
important epitopes in the antigenic profile revealed by the rabbit polyclonal 
antibodies.
Involvement of residues 127-150 in TCR binding is also supported by the 
work of Cullen et a l (1995) who found that substitution of alanine for histidine at 
position 135 does not inhibit binding to MHC II bearing A20 cells. This mutation
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does however affect interaction with the TCR and there is failure of the T-cell to 
produce IL-2, INF-y, or TNF-p.
The MHC II binding region of the toxin is thought to lie in the NH2  terminal 
domain, within residues 31-45 (Hurley et al, 1995), and mutation of the glycine 
residue at position 31 has been shown to abrogate binding to human monocytes (Kum 
et a l, 1996). This re-enforces the findings of Soos et al. (1993) who used synthetic 
peptides of TSST-1 to block binding of l'^^ labelled TSST-1 to MHC II displaying 
Raji and A20 cells. This work identified peptides 39-68 and 155-194 as being of 
important for MHC II binding. There is also X-ray crystallographic data which 
supports these results and demonstrates TSST-1 binding to the human MHC II 
molecule DRl by interaction between residues 50 and 53 on TSST-1 and residue 39 
of DRl {YAm etal, 1994).
The Mabs studied in this project appear to bind to the 12 and 16 kDa papain 
generated fi-agments (residues 88-194 and 53-194 respectively) in the western blot 
experiments, which do not include the NH2  terminal section of the toxin and as such 
would seem to indicate that they are not binding to epitopes involved in MHC II 
interactions. The results of the proliferation assays with both the mouse spleen cells 
and human peripheral blood lymphocytes show that not all the Mabs are effective in 
preventing proliferation. In fact only three of the eight Mabs (4 TSST 5.3, 10.3 and, 
116.3) have any neutralising ability, and therefore they must bind to or very close to a 
biologically important epitope. This is most likely in the TCR binding region of the 
toxin molecule, and this is supported by the lack of IL-2 expression when these Mabs 
are used. IL-2 production is an early event in T-cell activation (Takei et al, 1993) and 
precedes proliferation. Taken as a whole the results of the Western blot analyses, T-
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cell assays and the published information on the structure and function of the toxin 
indicate that these Mabs are most probably binding to the TCR binding region of the 
toxin which is contained within the COOH terminal region of the molecule (Hurley et 
ai, 1995, Cullen et a l, 1995). Whilst it cannot be ruled out entirely it appears that 
interaction of the toxin with the MHC II is probably not affected by these Mabs.
The use of Mabs as potential therapeutic agents would require that the Mab 
prevent toxin mediated cell proliferation and production of cytokines. This would 
minimise vascular leakage and fever induced by the over production of cytokines such 
as IL-1 and TNF. To this end optimum inhibition of toxicity may be achieved by an 
antibody which blocks binding to the TCR thereby preventing T-cell activation. An 
antibody which bound to the MHC II interaction site on the toxin may well "present" 
the toxin to the TCR itself, resulting in T-cell activation (Shimonkevitz et al, 1996). 
The results demonstrated here indicate that the Mabs which neutralise in vitro may be 
suitable for further study as potential therapeutic agents.
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Chapter 5 
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Chapter 5.
General Discussion.
5.1 Toxic shock syndrome.
Toxic shock syndrome has been noted in many cases where staphylococcal or 
streptococcal infections are evident. These include menstrual TSS (Shands et ai, 
1980; Davis et ai, 1980), infected bums (Cole and Shakespeare, 1990; Childs et ai, 
1994; Ed wards-Jones et ai, 1996) and some autoimmune diseases such as atopic 
dermatitis (Hofer et a l, 1995). The toxin-mediated effects can include cytokine 
release, proliferation of immune cells, vascular leakage, fever, nausea and dizziness 
(Chesney et al, 1984). These symptoms have a rapid onset and are potentially life- 
threatening (Gaventa et al, 1989; Alouf et al, 1991). Survivors can often suffer 
recurrence of illness (Chesney et al, 1984) and in menstmally-associated TSS they do 
not appear to retain immunological memory of the toxin (Chesney, 1989; Arvand and 
Hahn, 1996).
Current therapy involves the use of antibiotics to clear the microbial infection 
(Resnick, 1990, Chesney, 1989) and administration of hypotonic fluids to counter the 
loss of fluid caused by the illness (Resnick, 1990). In severe cases IVIG may be 
administered (Barry et al, 1992; Lamothe et al, 1995; Perez et al, 1997) to clear pre­
formed toxin from the bloodstream, but this treatment relies on the blood products 
used containing antibody to TSST-1 which is not always the case (Childs and 
Edwards-Jones, 1994). There is also the possibility that early administration of IVIG 
could blunt the immune response to this and other antigens (Chesney, 1989).
A specific, sensitive, rapid and reliable assay for the toxin in the blood or other 
body fluids would aid diagnosis and therapy in these clinical situations. This would.
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in turn aid the choice of treatment and more effective measures could be taken as early 
as possible in the disease process which may enhance patient survival rates.
5.2 Production, Purification and Primary Characterisation of Monoclonal 
Antibodies.
Mabs produced in this study were all of the IgGj isotype, and primary 
characterisation revealed that they did not cross react with other bacterial toxins 
including the staphylococcal enterotoxins. Purification was carried out by Protein G 
affinity chromatography to provide homogenous antibody solutions as assessed by 
SDS PAGE gel analysis. Two Mabs were chosen for assay development on the basis 
of their high binding affinities for TSST-1 in the presence of the chaotrophic agent 
3 M urea, and they did not compete for binding to the toxin.
5.3 ELISA Development.
Conjugation of the Mabs to HRP by the method of Nakane and Kawaoi (1974) 
produced detection reagents for use in ELISA assay development. This work allowed 
selection of the two Mabs which gave the highest sensitivity in the assay system 
which was improved further by using biotinylated tyramine and streptavidin HRP 
(Bobrow et al, 1989, 1991; Relie et al, 1991) to amplify the reaction so that as little 
as lOpg ml*^  of toxin could be detected in buffer. The reproducibility of the assay was 
then tested using inter and intra assay variation methods (Beer, 1993). These tests 
showed the assay to have good reproducibility with very low %CV values which 
indicates that the accuracy of the results is high.
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The amplified assay system was applied to the detection of toxin in serum and 
urine samples from healthy donors which had been spiked with purified toxin. These 
tests revealed that detection of toxin to the levels (0.5-0.01 ng ml'*) reported by other 
workers (Wells et al. 1987; Miwa et al, 1994) was achievable and so the ELISA was 
applied to the detection of TSST-1 in clinical samples. Urine, serum and plasma were 
obtained from various cases of suspected TSS where toxigenic staphylococci had been 
isolated.
The assay developed as part of this study failed to detect toxin in any of the 
clinical samples available, despite successful detection in tests using spiked control 
serum and urine. When the samples were analysed for antibodies to TSST-1 they were 
detected in most of the serum and plasma samples tested which may indicate that 
TSST-1 was not a causal agent in the disease process in these cases. The lack of toxin 
detection could however be due to other factors, for instance the samples used in this 
study were all transported at ambient temperature which may have permitted 
proteolytic degradation of the toxin, making it undetectable, or it is possible that free 
toxin was not circulating at the time the samples were taken.
The procurement of suitable clinical samples has proved extremely difficult, 
but if more could be obtained the suitability of the assay system could be further 
investigated. The lack of sufficient data is currently preventing a full evaluation of the 
efficacy of this method of detection for this particular toxin. If successful the assay 
may have applications in other disease scenarios where TSST-1 may be involved such 
as atopic dermatitis (Hofer et al, 1995; Lester et al, 1995) autoimmune disease 
involving B-cell activation and apoptosis (Hofer et al, 1996), recalcitrant 
erythematous desquamating disorder (Cone et al, 1992; Dondorp et al, 1994) and
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Kawasaki syndrome (Leung et al, 1993). Such an assay may also offer a possible 
veterinary application as TSST-1 and/or the staphylococcal enterotoxins have been 
implicated in pathogenesis of bovine mastitis (Yokomizo et al, 1995; Takeuchi et al, 
1996).
5.4 Biological activity
The results of the western blot experiments revealed that the Mabs were 
binding within the carboxyl terminal region of the toxin which has been identified as 
important in the biological function of the toxin (Edwin et a l, 1988; Cullen et al, 
1995), and the epitope mapping studies carried out using rabbit polyclonal anti-TSST- 
1 revealed several antigenic determinants in this area.
The carboxyl terminal region of the toxin is thought to be involved in TCR 
binding (Cullen et al, 1995; Hurley et al, 1995) which is a requisite for the biological 
activity of the toxin (Marrack and Kappler, 1990; Saha et al, 1996). Cross-linking of 
the TCR with MHC 11 molecules displayed on APC's by TSST-1 leads to T-cell 
activation which plays an essential role in pathogenesis (von Bonin et a l, 1995). That 
the neutralising {in vitro) Mabs described in this study are binding to the TCR binding 
region of the toxin could be a very important feature. It has been shown that TSST-1 
binds to the VP2  region of the TCR (Shimonkevitz et al, 1996) and it can induce 
expression of VP2  by activated T-cells (Takahashi et al, 1995; Hu and Zhu, 1996). 
The use of anti- VP2 Mab does not necessarily interfere with TSST-1 binding to the 
TCR (Makida et al, 1996). This suggests that in a potential therapeutic application 
the use of a Mab, or synthetic peptide which bound to the TCR to prevent toxin 
binding and MHC 11 cross linking may not necessarily prevent cell activation and the
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consequent release of cytokines characteristic of this disease (Goodglick and Braun, 
1994; Saha et al, 1996). A Mab such as those described here which binds to the toxin 
and prevents it binding to the TCR could however be a useful therapeutic tool.
Neutralisation of the toxin in vivo will reduce the cytokine activation normally 
associated with TSS (Goodglick and Braun, 1994). It has been demonstrated that T- 
cells bearing selected Vpj elements can bind and respond to TSST-1 directly without 
the involvement of MHC II structures (Dennig et a l, 1996) although T-cells 
responding to TSST-1 in the presence of APC's do produce much higher amounts of 
IL-2 (Takahashi et al, 1995; Dennig et al, 1996). In view of these facts a Mab which 
could bind to the toxin and prevent its interaction with the TCR could be very 
effective in limiting the severity of the illness.
Although binding of the Mabs to the toxin has been localised to a 12KDa 
segment at the COOH terminal end of the toxin the precise epitope to which the Mabs 
bind has not been identified. Indeed, there are several antigenic determinants within 
this region which were identified by epitope mapping experiments using polyclonal 
antibody. The lack of results from this procedure when carried out using the Mabs 
probably indicates that these antibodies bind to conformational rather than linear 
epitopes.
None of the Mabs produced during this study appear to bind to the toxin 
within the MHC II binding region. This is disappointing as binding to the MHC II or 
human HLA is important in the disease process and it has been shown that HLA-DR 
expression is increased in human TSS caused by TSST-1 (Arvand and Hahn, 1996). 
An antibody which was able to prevent binding to MHC II molecules may have 
proved very useful in studying the biological activity of the toxin. Eliminating binding
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to accessory cells would allow the effect of the toxin alone to be assessed. Since it has 
been determined that even without APC activity T-cells can bind and respond to 
TSST-1 (Dennig et al, 1996) or that a Mab bound to the MHC II binding region 
could 'present' the toxin to the TCR (Shimonkevitz et al, 1996) the use of Mabs as a 
therapeutic tool may be best achieved by using a combination of 2  antibodies, one 
binding to the TCR binding epitope and one to the MHC II epitope. This would 
ensure effective neutralisation of the toxins biological activity. Using Mabs as 
therapeutic agents in a toxin-mediated disease scenario would give a direct approach 
to therapy whereas the use of IVIG is more empirical - it is by no means definite that 
antibody to the agent in question is present in the Ig (Childs and Edwards-Jones, 
1994).
5.5 Conclusion.
Overall this project has successfully achieved some of its aims. The 
monoclonal antibodies have been characterised and a rapid very sensitive ELISA for 
TSST-1 has been developed. This assay can be used to detect small amounts of toxin 
in S. aureus culture supernatant fluids and early studies suggest the assay may be 
suitable for use with clinical samples from TSS patients after further evaluation.
The antibodies have also been used in in vitro assays using mouse spleen cells 
and human peripheral blood lymphocytes to assess their ability to neutralise the 
mitogenic activity of the toxin. Three of the Mabs have been found to neutralise the 
toxin in these assays.
The binding of the Mabs to the toxin has been localised to a 12KDa fragment 
encompassing the COOH domain of the molecule, which is believed to be involved in
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TCR binding. The ability of the Mabs to neutralise the toxin in vivo has yet to be 
established.
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5.5 Future work.
A primary objective of any future work should be to test more clinical samples 
in order that the suitability of the assay as a clinical tool can be fully assessed. Serum, 
plasma, urine or bums fluids could all be tested in this assay and results compared 
with clinical findings and other assay methods.
The second objective should be to test the effect of the Mabs on the toxin and 
its function in an in vivo study to establish whether the mitogenic effect of the toxin 
could be abrogated. There have been several attempts to establish an animal model of 
TSS, including the use of mice and primates, but rabbits are the only species to show 
TSS-like symptoms (de Azevedo, 1989). Most studies have used either sub-cutaneous 
whiffle balls (Scott et al, 1983) or mini osmotic pumps (Bonventre et a l, 1988), 
although an intra-vaginal tampon model in rabbits has been developed (Melish et al, 
1989). Whichever infection model is used TSST-1 producing strains and purified 
toxin induce death in rabbits (Scott et al, 1983; Bonventre et al, 1988) and symptoms 
observed in the rabbits are similar to those seen in humans. These include; fever, 
conjunctival hyperaemia, respiratory distress and shock, and blood chemistry changes 
such as increased creatinine and urea (de Azevedo, 1989). Post mortem changes 
parallel those seen in humans, e.g. congestion and oedema of various tissues, 
erythrophagocytosis in lymphoid tissue and liver triaitis (de Azevedo, 1989).
The use of purified TSST-1 in rabbits using the mini osmotic pump method 
(Bonventre et a l, 1988) allows the toxic effects of TSST-1 to be evaluated without 
interference from other bacterial products, and delivery of small amounts of toxin over 
a period of time, such as might occur in infection. The pump method also allows a set 
amount of toxin to be delivered reproducibly.
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As an alternative to the methods above, micro-encapsulated toxin could be 
used to induce symptoms of TSS. The toxin can be encapsulated in micro-particles of 
poly(lactide-co-glycolide) polymer (PLG; Jones et al, 1995 and 1996) which when 
injected sub-cutaneously into the animal undergoes non-enzymic hydrolysis to give 
lactic acid and glycolic acid and release the toxin. This method has all the advantages 
of the pump method, delivering a known quantity of toxin without interference from 
other bacterial products and the added advantage that surgical implantation is not 
required, which reduces stress on the animals.
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Appendix.
Single letter amino acid abbreviations.
Alanine A
Valine V
Leucine L
Isoleucine I
Proline P
Phenylalanine F
Tryptophan W
Methionine M
Cysteine C
Glycine G
Asparagine N
Glutamine Q
Serine s
Threonine T
Tyrosine Y
Lysine K
Arginine R
Histidine H
Aspartate D
Glutamate E
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